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Abstract 
 
The current clinical standard for diagnosis of prostate cancer (PCa) is 2D transrectal 
ultrasound (TRUS)-guided biopsy.  However, this procedure has a false negative rate of 21-
47% and therefore many patients return for repeat biopsies.  A potential solution for 
improving upon this problem is “fusion” biopsy, where magnetic resonance imaging (MRI) 
is used for PCa detection and localization prior to biopsy.  In this procedure, tumours are 
delineated on pre-procedural MRI and registered to the 3D TRUS needle guidance modality.  
However, fusion biopsy continues to yield false negative results and there remains a gap in 
knowledge regarding biopsy needle target selection. Within-tumour needle targets are 
currently chosen ad hoc by the operating clinician without accounting for guidance system 
and registration errors.  The objective of this thesis was to investigate how the choice of 
target selection strategy and number of biopsy attempts made per lesion may affect PCa 
diagnosis in the presence of needle delivery error. 
A fusion prostate biopsy simulation software platform was developed, which allowed for the 
investigation of how needle delivery error affects PCa diagnosis and cancer burden 
estimation.  Initial work was conducted using 3D lesions contoured on MRI by collaborating 
radiologists.  The results indicated that more than one core must be taken from the majority 
of lesions to achieve a sampling probability ≥ 95% for a biopsy system with needle delivery 
error ≥ 3.5 mm.  Furthermore, it was observed that the optimal targeting scheme depends on 
the relative levels of systematic and random needle delivery errors inherent to the specific 
fusion biopsy system. Lastly, PCa tumours contoured on digital histology images by 
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genitourinary pathologists were used to conduct biopsy simulations.  The results 
demonstrated that needle delivery error has a substantial impact on the biopsy core 
involvement observed, and that targeting of high-grade lesions may result in higher core 
involvement variability compared with lesions of all grades. 
This work represents a first step toward improving the manner in which lesions are targeted 
using fusion biopsy. Successful integration of these findings into current fusion biopsy 
system operation could lead to earlier PCa diagnosis with the need for fewer repeat biopsy 
procedures. 
 
Keywords 
Prostate biopsy, prostate cancer diagnosis, image-guided biopsy, 3D fusion biopsy planning, 
biopsy target selection, 3D ultrasound, magnetic resonance imaging, needle guidance error, 
image registration error  
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Chapter 1 
 
1 Introduction 
 
The work in this thesis is primarily concerned with modifications to the strategies 
used in performing magnetic resonance imaging-targeted, 3D transrectal ultrasound 
(TRUS)-guided “fusion” prostate biopsy.  “Fusion” biopsy refers to the use of MRI-3D 
TRUS fusion to allow targeting of MRI-defined lesions using a 3D TRUS biopsy system. 
Such biopsy systems were developed as a potential solution to the high false negative rate 
of clinical standard 2D transrectal ultrasound-guided biopsy.  However, while such 
systems have shown an increase in cancer detection rate of prostate biopsy, fusion biopsy 
continues to yield false negative results.  Therefore, a need remains for improvement in 
detection rate for timely diagnosis of PCa while it is still small and curable.  There exists 
substantial research into prostate imaging and biopsy needle guidance, but there remains 
a gap in knowledge regarding biopsy plan optimization. Within-tumour needle targets are 
chosen ad hoc in fusion biopsy without accounting for uncertainties due to guidance 
system and registration errors, and irregular tumour sizes and shapes. Therefore, the work 
presented in this thesis is intended further investigate whether optimization of needle 
target planning with appropriate uncertainty propagation may lead to an improved 
prostate cancer detection rate. 
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1.1 Prostate cancer epidemiology and impact 
Prostate cancer (PCa) is the most commonly diagnosed non-cutaneous cancer in 
North American men1.  Approximately one in seven Canadian men will develop PCa and 
1 in 29 men will die from the disease.  In Canada, 21300 new cases of PCa were 
projected for 20171. 
While PCa is a highly treatable disease, with a 5 year net survival of 95% for 
those diagnosed1, those who receive treatment often face substantial costs to quality of 
life as a result of the treatment.  Regardless of patient age, the anatomical location of the 
prostate relative to the neurovascular bundles, bladder, rectum and urethra means that 
conventional treatments such as prostatectomy, external beam radiation therapy and 
brachytherapy lead to decreased urinary, bowel and sexual health2. 
Perhaps one of the largest challenges with PCa is that its aggressiveness can vary 
widely, as measured by the Gleason grade of the cancer3.  Due to this variety of PCa 
grades, some PCa patients need urgent care while others have indolent cancers that are 
unlikely to be fatal. 
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1.2 Prostate cancer diagnosis 
1.2.1 Digital rectal examination 
Digital rectal exam (DRE) is an exam in which a physician palpates the prostate 
gland through the rectal wall.  DRE generally performs poorly in the detection of PCa 
with a positive predictive value between 17-38%4; however it is more sensitive to 
detection of PCa in the peripheral zone (PZ) of the prostate, as the PZ is adjacent to the 
rectal wall.  In cases of PCa in the PZ (where 70-80% of prostate cancers form5), the 
physician may detect a hardening of tissue that would be particularly suspicious if it is 
asymmetric with the contralateral side of the gland.  As this test suffers from a generally 
poor sensitivity outside of the PZ and misses most early stage tumours6, it is often used in 
conjunction with the prostate specific antigen (PSA) test. 
 
1.2.2 Prostate specific antigen test 
Prostate specific antigen (PSA) is a glycoprotein produced by the prostate gland.  
It was shown by Stamey et al7 that the PSA levels in the blood correlated with PCa stage.  
Generally, a PSA level of 4.0 ng/mL or higher is considered suspicious for the presence 
of PCa8.  However, the PSA test suffers from numerous sources of inaccuracy, as sources 
other than PCa can cause elevated PSA levels in the blood. Some examples include 
benign prostatic hyperplasia (BPH), prostatitis and previous prostate biopsies9.  In order 
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to detect cancers at an early and treatable stage, a combination of DRE and PSA testing is 
used in Canada to screen asymptomatic men.  This method of PCa screening remains 
controversial due to the balance of benefit achieved through treating aggressive cancer 
early versus the decreased quality of life for men with indolent cancers who receive 
treatment. 
 
1.2.3 2D transrectal ultrasound (TRUS)-guided biopsy 
If there is suspicion that a patient has PCa, they will be referred for a prostate 
biopsy, the current standard for definitive diagnosis of PCa.  In this procedure, tissue 
samples are taken from the prostate using a biopsy needle, either through the rectal wall 
(transrectally) or through the perineum (transperineally) and the samples are then sent to 
pathology in order to assess the presence and Gleason grade of cancer3. In particular, 2D 
transrectal ultrasound (TRUS)-guided biopsy is the current clinical standard for PCa 
diagnosis.  However, as PCa is generally not detectable on ultrasound10-12, 6-12 biopsy 
cores are taken using a systematic targeting scheme which primarily samples the 
peripheral zone of the gland where most cancers are located (Fig. 1-1).  However, this 
approach has been shown to have upwards of a 21-47% false negative rate in terms of 
PCa diagnosis13, 14, and therefore many patients are required to return to the clinic for 
repeat biopsies.  Furthermore, this method may lead to an underestimation or an 
overestimation of a PCa patient’s true Gleason score15. 
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Figure 1-1: 12 needle target locations for an “extended-sextant” prostate biopsy 
targeting scheme. 
 
After biopsy, tissue from each core is examined under a microscope in order to 
estimate cancer burden for the patient using the TNM Classification of Malignant 
Tumours system8 (where TNM stands for tumours, nodes and metastases). In this 
system, PCa of the primary tumour is classified into stages T1 – T4.  The criteria for 
stages T1 through T4 are described in Table 1-1.  Additional to TNM staging of PCa, 
three other important measures for estimation of cancer burden include the Gleason 
scores of tumours sampled through biopsy, the number of biopsy cores containing 
cancer tissue, and the core involvement obtained (i.e. the proportion of the biopsy core 
which contains tumour tissue)8. 
Left Right
Superior
Inferior
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Table 1-1: TNM staging system for PCa: primary tumour (T) 
Stage Sub-stage Criteria 
T1 - Clinically inapparent tumour, not palpable or visible by imaging. 
- T1a Tumour incidental histologic finding in 5% or less of resected tissue. 
- T1b Tumour incidental histologic finding in more than 5% of resected 
tissue. 
 T1c Tumour identified by needle biopsy 
T2 - Tumour confined within prostate 
- T2a Tumour involves one half of one lobe or less 
- T2b Tumour involves more than one half of one lobe, but not both lobes. 
- T2c Tumour involves both lobes 
T3 - Tumour extends through prostatic capsule 
- T3a Extracapsular extension 
- T3b Tumour invades the seminal vesicles. 
T4 - Tumour invades structures other than seminal vesicles: bladder, pelvic 
wall and/or levator muscles. 
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However, grading biopsy tissue is a challenging issue, and may contribute to the 
problem of overtreatment of men with indolent PCa16, 17.  In an attempt to reduce the 
overtreatment of PCa, there has been a push in the past two decades to place men with 
low risk cancers on active surveillance.  However, it has been shown that 25-37% of men 
who are placed on active surveillance after receiving 2D TRUS-guided biopsy are 
removed from surveillance to receive treatment within 5 years18, 19.  This may be due to 
underestimation of tumour grade on initial biopsy, interval changes in the tumour 
histology, and/or patients opting for definitive treatment, however this indicates that 
improved methods for per-patient estimation of PCa burden are needed. 
 
1.2.4 Prostate cancer imaging techniques 
1.2.4.1 Ultrasound Imaging 
Due its portability, inherent real-time nature, and relatively low cost compared to 
magnetic resonance imaging, transrectal ultrasound (TRUS) is currently the most 
commonly used modality for image guided prostate biopsy and other needle-based 
therapies such as brachytherapy.  TRUS allows easy visualization of zonal anatomy and 
is also important for estimation of prostate volume primarily for calculation of PSA 
density for cancer staging8.  In this imaging modality, a transducer which contains 
transmitting elements generates ultrasonic waves20, which in the context of TRUS 
imaging operate in the range of 5-10 MHz.  As discussed further in Section 1.2.5.1, some 
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TRUS systems contain enhanced functionality which allows for the reconstruction of a 
full 3D volume using multiple single-plane 2D TRUS images.  The acquisition rate of 2D 
TRUS imaging is generally 10-20 frames per second, while acquisition of a 3D TRUS 
image can take upwards of 13 seconds21. A labelled 2D TRUS image of a prostate is 
shown in Figure 1-2. 
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Figure 1-2: An in vivo 2D TRUS image of the prostate.  The outline of the prostate is 
shown in red.  Patient left and right are indicated, as well as the locations of the urinary 
bladder and rectum. 
 
In-vivo ultrasound images are produced by detecting ultrasound waves that are 
reflected as they penetrate through tissue and anatomical structures of varying density.  
The degree of reflectance is dependent on the acoustic impedance between two different 
layers of material or tissue.  The structures which reflect the most ultrasound waves 
Urinary Bladder
Rectum
Right Left
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appear bright in the resultant image (hyperechoic), while the structures which reflect the 
least amount of ultrasound waves appear dark (hypoechoic).  In the context of prostate 
imaging, two examples of structure which appear hyperechoic are the pubic bone and 
calcifications within the gland.  Conversely, fluid filled structures such as the seminal 
vesicles, bladder and cysts appear hypoechoic.   
While in some instances PCa in the PZ can appear hypoechoic on TRUS22, it 
generally has a low sensitivity (35-91%) and specificity (24-81%) with respect to 
detection of PCa10-12, 23-26.  As discussed in Section 1.2.5.2, due to the limitations of PCa 
imaging using TRUS, there have been systems developed for MR-guidance of prostate 
biopsies.  However, due to the upfront cost, time and technical challenges required to 
perform biopsies using these systems, TRUS-guided biopsy remains the standard for 
prostate biopsy guidance in North America. 
 
1.2.4.2 Magnetic resonance imaging 
Magnetic resonance imaging (MRI) has shown to be effective for detection, 
localization and staging of PCa27.  A major advantage of MRI compared to TRUS is that 
it allows for high contrast between soft tissues using different image acquisition 
sequences, therefore providing richer anatomical detail compared to what can be 
achieved using TRUS.  However, the performance of specific MRI sequences for 
detection and localization of PCa can vary widely depending on which sequence is used.  
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Currently the most common MRI sequences used in PCa imaging are T2-weighted 
imaging, T1-weighted dynamic contrast enhanced imaging and diffusion weighted 
imaging. Examples of these image sequences are shown in Figure 1-3.  These three 
sequences are the cornerstones of the Prostate Imaging Reporting and Data System (PI-
RADS), designed for assessment of PCa risk on MRI28, 29.   
T2-weighted (T2W) MR imaging is one of the most common anatomical MRI 
sequences, and is sensitive to transverse relaxation of precessing protons after a radio 
frequency pulse.  T2W prostate images provide detailed anatomical maps of prostate 
zonal anatomy, allowing clear differentiation between the peripheral zone, transition zone 
and central zone30.  In terms of detection and localization of PCa, T2W sequences are 
most useful in the peripheral zone, where cancer can be detected as a region of 
hypointensity (i.e. appearing dark on T2W MRI) compared to the contralateral side of the 
PZ.  It has been shown that the greater the contrast between the hypointense region and 
the typically bright normal tissue in the PZ, the higher the Gleason grade of the detected 
cancer 30, 31.  Overall, T2W interpretation for PCa detection is limited by the similar 
appearance of cancerous and non-cancerous tissue abnormalities, including BPH, 
atrophy, chronic prostatitis and also hemorrhaging following prostate biopsy32. 
A common functional technique for the detection of PCa is T1-weighted (T1W) 
dynamic contrast enhanced (DCE) sequences.  In a standard DCE scan, the patient is 
injected with a contrast agent (such as gadolinium) and imaged using a T1W imaging 
sequence, typically with a high temporal resolution (<10 seconds).  This imaging starts 
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before the contrast agent is injected, allowing the full “wash-in” and “wash-out” of the 
contrast agent to be observed.  It has been shown that cancerous tissues exhibit an earlier 
enhancement (i.e. wash-in) and earlier wash-out compared to normal healthy tissue.  The 
qualitative analysis of DCE-MRI in the context of prostate imaging is based on the 
general assumption that tumour blood vessels are leaky and more readily enhance are 
injection of the contrast agent, expressed by a fast exchange of blood and contrast agent 
between capillaries and tumour tissue33.  This is thought to be caused by higher 
permeability of new blood vessels formed due to angiogenesis associated with PCa34.   
While qualitative analysis of DCE-MRI is widely practiced, quantitative analysis 
of these images has been increasing in popularity as well, due to more widely available 
software designed to perform this analysis, and a growing consensus of the utility of this 
approach.  Several pharmacokinetic models have been proposed for quantitative analysis 
of DCE-MRI35-38, and in general these models are based on determining the rate of 
contrast exchange between plasma and the extracellular space using transfer rate 
constants, which are known to be elevated in many cancers, including PCa39, 40.  These 
quantitative methods have the potential for standardization across various imaging 
sequences and parameters. 
Another functional technique that is now a critical component of prostate MRI is 
diffusion weighted imaging (DWI).  Unlike the dynamic DCE sequence, DWI is a static 
sequence that does not require injection of a contrast agent, as it used to produce image 
contrast that is proportional to the diffusion of water molecules.  A decrease in the 
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magnitude of water diffusion is observed with increased cellular density associated with 
PCa.  By acquiring multiple diffusion weighted images with different b-values (which is 
a parameter that adjusts the level of diffusion weighting), this allows the computation of 
post-processed apparent diffusion coefficient (ADC) maps.  It has been shown that PCa 
appears as a hyperintense region on high b-level DWI, while it appears as a hypointense 
region on ADC maps28.  Furthermore, ADC values are correlated with the Gleason score 
of PCa, potentially allowing for improved diagnosis of more aggressive cancers41-44. 
 
 
Figure 1-3: In vivo MR imaging showing the same axial slice within a prostate, showing 
(A) a T2W image, (B) an image from the T1W DCE sequence, and (C) an ADC map 
calculated from the DWI sequence. 
 
1.2.4.3 Challenges with lesion delineation on imaging 
Despite the consensus of utility of MRI in PCa imaging, prostate volumes 
estimated by radiologists on multi-parametric MRI (mpMRI) consistently overestimate 
A B C
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histological reference volumes45.  This disagreement between lesions contoured on MRI 
and histologic cancer leads to challenges in how to best target lesions with biopsy 
needles, as well as defining gross volumes and clinical target volumes for PCa treatment. 
However, despite mpMRI overestimating volume compared with histologic 
reference volumes, in the context of prostate focal therapy, 95% histologic coverage 
margins were 8 mm (Gleason score ≥ 6) and 6 mm (Gleason score ≥ 7) expansions from 
the gross tumour volumes (GTVs) defined by radiologists on MRI46.  This is likely due to 
fact that when considering histologic coverage of clinical treatment volumes, the shape of 
the lesion must also be considered, as it is possible to overestimate lesion volume on MRI 
while also not achieving complete coverage of the lesion with the MR-defined contour. 
While expansion of the GTV is a promising means to achieve better coverage for 
prostate therapy, this does not address the challenge of how to adjust biopsy needle 
targeting to deal with the disagreement between MRI contours and histologic cancer 
coverage.  This is a field of research which requires further investigation. 
 
1.2.5 3D-guided biopsy systems 
1.2.5.1 MR-3D TRUS fusion biopsy 
The Artemis (Eigen, Grass Valley, CA) is a biopsy system developed by Aaron 
Fenster’s research group at Robarts Research Institute47, and involves attaching any 
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standard end-fire 2D TRUS probe to a mechanical tracking device which monitors the 
real-time 3D orientation of the probe.  A 3D TRUS image is then acquired by rotating the 
probe around its axis.  An example of a 3D TRUS fusion biopsy system interface is 
shown in Fig. 1-4.  As this mechanical tracking mechanism can only track the location of 
the probe itself, an additional motion compensation algorithm is required to compensate 
for patient motion48.  While Artemis is one commercially available fusion biopsy system, 
there now exist numerous other MRI-targeted, 3D TRUS guided biopsy systems for PCa 
detection.  UroNav (Invivo, Gainesville, FL), bkFusion (bk Ultrasound, Peabody, MA), 
and TargetScan (Envisioneering Medical Technologies, St. Louis, MO) are three 
examples of other systems developed for fusion prostate biopsy. 
The development of 3D TRUS-guided biopsy systems allows for improved spatial 
information relative to 2D-TRUS, by providing a 3D volume image as opposed to solely 
a 2D plane.  As defined in the beginning of this Chapter, a 3D TRUS biopsy system with 
MRI-3D TRUS fusion of biopsy targets is known as “fusion” biopsy.  In this approach, 
suspicious regions to be targeted by biopsy are delineated on MRI, and then registered 
onto the 3D TRUS image volume.  Cool et al. showed that fusion biopsy produced 
significantly higher (p < 0.01) positive biopsy core rates, mean Gleason scores and  
volumes sampled, compared to 2D TRUS-guided 12-core systematic biopsy49.  Roethke 
et al. observed a 29% cancer-positive core rate for targeted fusion prostate biopsy, with 
cancer detected in 42% of patients50. Puech et al. determined that cancer was detected in 
69% of patients when undergoing fusion biopsy compared to 50% of patients for 
systematic TRUS-guided biopsy51, while Natarajan et al. determined that 33% of targeted 
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fusion biopsy cores contained cancer-positive tissue compared to 7% of biopsy cores for 
non-targeted TRUS guided biopsy52. Volkin et al. investigated the effectiveness of fusion 
biopsy specifically for anterior lesions, and observed a cancer detection rate of 40% for 
fusion biopsy compared to a 26% detection rate for systematic TRUS-guided biopsy 
cores taken from the equivalent anatomic sextent of the prostate53. Conversely, Tonttila et 
al. did not observe any significant improvement in terms of clinically significant cancer 
detection rate from the use of MRI-TRUS fusion targeted biopsy vs. the extended sextant 
standard for target selection54. However, it is worth noting that of the three operating 
clinicians in their study (with 5, 10 and 15 years of 2D-TRUS guided prostate biopsy 
experience respectively), none had any prior experience with targeted biopsies. 
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Figure 1-4: The software interface of the prototype for the Artemis biopsy system, 
described in Bax, J., et al., Med. Phys. 35(12), 2008.47 
 
1.2.5.2 MR only-guided biopsy systems 
An alternative to MR-3D TRUS “fusion” biopsy is MR-targeted, MR-guided 
biopsy, wherein both lesion delineation and biopsy targeting are done under MR-
guidance55, 56.  An advantage of these systems over fusion biopsy is that they remove the 
need to perform image registration between modalities, removing some sources of 
registration error.  However, MR-TRUS fusion biopsy has the advantage of low cost, 
widespread availability, real-time imaging, and is compatible with standard biopsy 
needles.  Contrary to MR-targeted, MR-guided biopsy, fusion biopsy is also compatible 
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with the close access to the TRUS probe entry point required to accurately position 
biopsy needles, with patient positioning that is concordant with the usual training of the 
urologist. 
Numerous studies have been conducted which show the clinical feasibility of 
MR-only systems57-64. One such system has a mean procedure time of 80 minutes57, 
indicating that procedure cost and patient comfort may be the leading impediments of 
widespread availability of such systems.  However, further studies of clinical usefulness 
of MR-guided biopsy versus TRUS-guided biopsy are warranted57.  Furthermore, a study 
has shown that MR-guided prostate biopsy is also characterized by substantial needle 
placement error, with a mean and standard deviation of 6.5 ± 3.5 mm for targeted 
biopsies58, while further phantom experiments showed significant needle placement error 
due to needle deflection while using a needle with an asymmetrically beveled tip (4.6 ± 
0.4 mm in gelatin, 8.7± 0.8 in bovine muscle tissue).  However, needle deflection error 
was greatly reduced through using a symmetrically beveled needle (0.8 ± 0.6 mm in 
gelatin, 1.1± 0.5 in bovine muscle tissue). Misalignment of the needle template guide 
used for transperineal insertion also contributed a needle placement error of 1.5 ± 0.3 
mm.  These results indicate that further studies must be completed to determine if there 
are any potential benefits in needle placement error achieved through MRI-only guided 
prostate biopsy over MRI-targeted, 3D TRUS-guided fusion biopsy. 
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1.3 Histological examination and prostate cancer 
1.3.1 Prostate biopsy histology 
Histological analysis of biopsy tissue is necessary for obtaining definitive 
diagnosis of PCa in patients with suspicious screening results.  It is also highly important 
for disease burden monitoring in active surveillance populations and for confirmation of 
disease recurrence in some post-treatment patients experiencing biochemical recurrence.  
The value of histology in the workflow of PCa diagnosis and treatment selection is due to 
the high prognostic importance of the Gleason grading of PCa3.  Since it was initially 
developed in the 1960s, this system for assessing the aggressiveness of PCa has been 
incorporated into numerous internationally recognized guidelines for PCa treatment8, 65 .  
Considered conjointly with the Gleason score and anatomical location of biopsy-
confirmed PCa, the core involvement (as described in Section 1.2.3), or proportion of 
each biopsy core which contains tumour tissue, is an important measure for estimation of 
tumour burden and therefore treatment selection for patients.  The percent core 
involvement is measured with respect to an 18 mm long biopsy core, as detailed by the 
National Comprehensive Cancer Network Practice Guidelines in Oncology: Prostate 
Cancer8.  In general, a core involvement of 50% is an important threshold, as a lesion 
with a Gleason score < 7 and core involvement < 50% may be deemed to be clinically 
insignificant, while a lesion with Gleason score < 7 and core involvement ≥ 50% could 
be deemed clinically significant8, 65. 
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However, due to the finite nature of biopsy needle cores (on average biopsy 
samples account for approximately 0.2% of total prostate volume), histological analysis 
of biopsy tissue may not always reflect the true grade and extent of PCa for the patient. In 
fact, it is reported to have a 30-40% risk of under sampling clinically significant lesions66-
68.  Therefore, histological analysis of biopsy tissue may lead to underestimation of 
cancer burden for many patients. 
 
1.3.2 Clinical relevance of post-prostatectomy histology 
Compared to biopsy cores, histological analysis of the entire prostate gland 
obtained after prostatectomy can provide a complete picture of the extent and Gleason 
grade of all PCa within a given patient’s prostate.  While this is very useful for predicting 
disease progression after prostatectomy for patients, this method requires a whole-gland 
prostatectomy before histological analysis. Therefore, this inherently limits the study 
population to men who have already received prostatectomy for diagnosed PCa, 
potentially leading to an overrepresentation of high-grade PCa in the dataset compared 
with low-grade. 
Despite this limitation, histological data of post-prostatectomy tissue provides a 
highly useful reference standard for grade and location of PCa31, 39, 44, 46, 69-72.  However, 
these data are inherently biased toward patients with high-risk PCa (as these are the 
patients who generally receive prostatectomy), and do not provide generalizable findings 
related to men in low-risk PCa cohorts.   
21 
 
 
 
1.3.3 Image registration of post-prostatectomy histology and in-
vivo MRI 
As discussed in Section 1.2.4.3, there are often disagreement between lesions 
contoured on MRI and histologic cancer.  While whole-gland histology can only be 
obtained from patients who have already received a prostatectomy to treat their diagnosed 
prostate cancer, such histological data also provide a useful method for validation of MR-
defined lesions.  As MR-defined lesions are used to determine needle sampling locations 
for fusion biopsy systems, their validation against prostate histology may provide useful 
lessons with respect to how lesion targeting can be improved for fusion biopsy. 
Our group has developed a method for registration of post-prostatectomy 
midgland histology with in-vivo MRI, with a target registration error (TRE) ≤ 2 mm46, 73, 
74.  In order to perform this registration, in-vivo MRI images were obtained from each 
patient prior to surgery.  After surgery, excised prostate specimens were pierced with 
three hollow needles with cotton threads lined within them such that the threads remain 
when the needles are removed.  Seven strands of lamb kidney were also fixed to the 
surface of the gland.  Both the thread and lamb kidney were treated with a gadolinium-
based contrast agent to be used as MRI-visible fiducial markers, while the thread was 
also treated with ink.  An ex-vivo MRI scan was then performed on the specimen before 
histological processing.  After the ex vivo scan, the internal threads were removed and 
the prostate midgland was sliced into approximately 4 mm transverse slices, while both 
the apex and base were sliced sagitally.  As the internal threads were also treated with 
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ink, this ink can be seen around the edge of each hole created by an internal thread, 
allowing them to be distinguished from other tears or luminal areas. All slices were 
scanned using a slide scanner and then contoured for PCa by a physician trained in PCa 
morphology.  All contours were subsequently confirmed by a genitourinary pathologist. 
The co-registration of contoured midgland histology with in-vivo MRI was 
completed in two main steps.  Registration of the histology slices to ex-vivo MRI was 
completed using a semi-automatic affine transformation algorithm which mapped each 
histology slice to the best matching plane on the ex vivo image, using the relative 
locations of the external and internal fiducial strands.  The ex-vivo to in-vivo MRI 
registration step was then completed using a custom-built, interactive thin-plate spline 
transformation extension for 3D Slicer.  This registration involved manual placement of 
30-50 fiducial points on corresponding regions of interest in both the in-vivo and ex-vivo 
image volumes.  After fiducials were placed, the ex-vivo volume (and hence the 
histology slices matched with the ex-vivo volume) was deformed to match the in-vivo 
volume. 
This dataset of prostate histology aligned with in-vivo MRI allows for direct 
comparison of delineated cancer on histology and in-vivo imaging obtained for the 
patient prior to surgery.  This also allows for comparison of radiologist delineated regions 
of suspicion on MRI with locations of cancerous tissue as confirmed by histology.  As 
discussed further in Chapter 5, this data can be used to evaluate the Gleason score and 
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core involvement of PCa contained within a simulated biopsy core, when MR-defined 
lesions are used to select biopsy needle target locations. 
 
1.4 3D TRUS-guided fusion biopsy challenges 
1.4.1 Previous work in this field 
3D TRUS-guided “fusion” biopsy systems allow for improved spatial information 
relative to 2D TRUS and allow for MRI targeting via image registration47, 75-78.  One 
fusion biopsy system has shown improved positive core rates of 30.4% (compared to 
7.1% for 2D TRUS) and 42.3% (compared to 25.6% for 2D TRUS) for moderate and 
high suspicion lesions respectively49.  There exists research into accurate multi-modal 
image registration from MRI-3D TRUS, as well as algorithms for compensation of 
prostate motion during the biopsy procedure48, 75, 79.  A systematic review was conducted 
by Valerio et al, collecting 14 papers which compared MRI-TRUS fusion targeted biopsy 
versus 2D TRUS-guided systematic biopsy. They found that MRI-TRUS fusion biopsy 
detected more clinically significant cancers using fewer cores compared with systematic 
biopsy (median 33%, range 13-50% for fusion biopsy; median 24%, range 5%-52% for 
systematic biopsy).  Fusion biopsy also led to the detection of some clinically significant 
cancers that would have been missed by standard biopsy alone (median 9%, range 5-
16%)80. 
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While this work focuses on MRI-TRUS fusion using image registration software, 
another approach to TRUS-guided biopsy of prostate MRI-defined lesions is “cognitive 
registration.” This approach involves intuitive visual alignment between MRI lesions and 
TRUS guidance81.  However, consensus has not yet been reached regarding the 
superiority of the cognitive vs. software fusion approaches. Two studies reporting that 
biopsy targeting of clinically significant MRI lesions using cognitive registration resulted 
in inferior cancer detection rates compared with MRI-TRUS fusion82, 83, while another 
study found no significant difference in cancer detection rates between the two 
approaches54.  It should be noted that in the study which saw no significant difference in 
detection rates, the three collaborating urologists (with 5, 10 and 15 years of TRUS-
guided biopsy experience respectively) had no prior experience performing MRI-targeted 
fusion biopsies.  Further investigation is warranted, as it may be that small but still 
clinical significant tumours may benefit more from MRI-TRUS fusion over cognitive 
registration, compared with larger tumours. 
The volume of research cited in this section indicates the value of MRI-targeted 
biopsy and motivates our goal to further optimize this procedure.  In particular, there 
remains a lack of knowledge in terms of target optimization for placement fusion biopsy 
needles.  While errors leading to uncertainty in biopsy needle placement can be measured 
for any commercially available fusion biopsy system, these errors are not apparent to an 
operating physician using these machines to perform prostate biopsy.  At the time of the 
writing of this thesis, the author is aware of only one other study, by van de Ven et al.84, 
which provides insight into a potential avenue for further improvement of the positive 
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core rate. The authors estimated the maximum allowable TRE of MRI-3D TRUS 
registration for correct grading of 95% of ADC-determined high Gleason grade tumour 
components of peripheral zone PCa with fusion biopsy of sphere-shaped tumours84. The 
results of that study lead to the observation that the positive core rate is related to the 
biopsy system error in delivering the needle to the intended tumour target.  
Based on this observation, one point of view is that a fusion biopsy system must 
deliver needles to targets with no more than some maximum needle delivery error to 
provide a clinically useful positive core rate for all tumours of clinically significant sizes. 
Another perspective is that for a fusion biopsy system with a given needle delivery error, 
some (larger) tumours can be sampled with a clinically desired probability (e.g. 95%) in a 
single biopsy core, and other (smaller) tumours will require more than one attempt in 
order to achieve the clinically desired probability of sampling the tumour in at least one 
of the cores taken. In principle, if the number of biopsy samples required for each tumour 
in a practical biopsy scenario is determined (within a reasonable limit for the number of 
biopsy cores), the positive yield of contemporary fusion biopsy systems could be 
increased by optimizing the number and within-tumour placement of targets for each 
tumour.  The research presented in this thesis takes the latter perspective, investigating 
varying numbers of biopsy attempts and targeting strategies for fusion prostate biopsy. 
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1.4.2 Clinical challenges 
While touched on in Sections 1.2 and 1.4.1, this section enumerates the specific 
clinical challenges in prostate biopsy that are addressed by this thesis. 
 
1.4.2.1 Uncertainties in biopsy needle delivery 
As mentioned in Section 1.4.1, 3D TRUS-guided fusion biopsy systems utilize 
accurate multi-modal image registration from MRI-3D TRUS, as well as motion 
compensation algorithms used during the biopsy procedure.  However, each step in the 
fusion biopsy pipeline is inherently characterized by non-zero error.  Four main sources 
of error include (1) MRI-TRUS registration, (2) Intersessional TRUS-TRUS registration, 
(3) intraprocedural registration for compensation of prostate motion and (4) biopsy 
needle guidance error of the system.  The errors associated with each of these steps for 
the Artemis system are as follows.  (1) A 3D nonrigid MRI-TRUS registration method 
was shown to have a median whole-gland target registration error (TRE) of 1.76 mm75.  
(2) An intersession TRUS-TRUS registration method has been shown to have a mean 
whole gland TRE of 2.15 mm79. (3) An intrasession rigid registration to compensate for 
prostate motion during fusion biopsy was shown to have a mean TRE of 1.63 mm48.  (4) 
The average needle delivery error for the Artemis fusion biopsy system was estimated to 
be 1.2 mm47. 
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Therefore, without accounting for the uncertainties associated with the 
registration and needle delivery errors described above, the biopsy needle of a fusion 
biopsy system may not be sampling the exact location intended by the operating clinician.  
The work presented in Chapter 2 investigates how these errors in biopsy needle 
placement affect the probability of successfully sampling prostatic tumours when making 
only one biopsy attempt. 
 
1.4.2.2 Lesion targeting approaches 
As discussed in Sections 1.2.5.1 and 1.3.3, it has been found that fusion prostate 
biopsy detects more clinically significant cancers using fewer cores compared with 2D 
TRUS-guided systematic biopsy, and led to the detection of clinically significant lesions 
that would have been missed by systematic biopsy alone80.  However, in the numerous 
studies comparing the two prostate biopsy approaches, the intended within-lesion biopsy 
needle targets were selected in an ad-hoc manner, where the errors associated with biopsy 
needle delivery were not considered when deciding the placement of targeted biopsies51-
60. 
Chapter 3 compares two different prostate lesion targeting strategies in the 
presence of practical needle delivery errors of 3D TRUS fusion biopsy systems, and how 
they affect both the probability of obtaining any amount of tumour tissue in the biopsy 
core, and the probability of obtaining a core involvement ≥ 50%. 
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1.4.2.3 Lesion delineation on multi-parametric MRI 
As discussed in Section 1.2.4.3, prostate volumes estimated by radiologists on 
MRI consistently overestimate histological reference volumes45, while also the gross 
tumour volumes defined by radiologists require an 8 mm expansion in order to achieve 
95% histological coverage46.  This shows that while MR-defined lesions volumes are 
consistently larger than the histological reference volumes, they still generally do not 
cover the entirety of the tumour as confirmed by histology.   
While expansion of the GTV allows for better coverage of the lesion for prostate 
therapy, due to the finite nature of biopsy needle sampling and the small diameter of each 
needle, a GTV expansion alone does not address the challenge of how to adjust biopsy 
needle targeting to deal with the disagreement between MRI contours and histologic 
cancer coverage Chapter 4 investigates how needle delivery error affects the sampling 
probabilities of PCa of all Gleason grades and high grade-only cancer, using lesions as 
delineated on prostate midgland histology.   
 
1.5 Thesis hypothesis and objectives 
In order to address key gaps in knowledge with regards to biopsy needle target 
selection for MRI-targeted, 3D TRUS-guided fusion prostate biopsy, the central 
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hypotheses of this thesis detailed in Section 1.5.1 were tested through the completion of 
the specific research objectives listed in Section 1.5.2.  In doing so, this work has led to 
first steps toward improving the manner in which lesions are targeted using fusion 
biopsy, potentially supporting earlier diagnosis and more accurate characterization of 
PCa while it remains localized to the gland and curable. 
 
1.5.1 Hypothesis 
The two central hypotheses of this work are enumerated as follows: 
1) The majority of clinically significant prostate lesions require more than one biopsy 
attempt to achieve a probability ≥ 95%  of obtaining a PCa-positive sample for practical 
needle delivery errors observed in MRI-targeted, 3D-TRUS-guided fusion biopsy 
guidance. 
2) More than one biopsy attempt is required to achieve a probability ≥ 95% of obtaining 
a PCa-positive sample with core involvement ≥ 50% (see Section 1.3.1) from clinically 
significant prostate lesions which are large enough for such a core involvement to be 
obtained. 
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1.5.2 Research objectives 
1) Adaptable biopsy simulation platform: to develop a software platform allowing for 
the simulation of multiple biopsy attempts and varying targeting strategies, given biopsy 
system error characteristics and 3D tumour shapes. 
2) Impact of biopsy needle delivery errors on probability of obtaining a tumour 
sample: to determine how the probability of sampling 3D tumour shapes in one biopsy 
attempt is affected by various amounts of needle delivery error characterizing fusion 
biopsy systems. 
3) Impact of targeting strategy on biopsy sampling: to determine the impact of using a 
ring versus a centroid targeting scheme on tumour sampling probabilities and tumour 
core involvement obtained when making multiple biopsy attempts, in the presence of 
both systematic and random errors. 
4) Impact of biopsy needle delivery error on pathologic cancer risk assessment: to 
investigate how biopsy needle delivery error affects the measure of core involvement and 
estimation of Gleason score from simulated biopsy cores contents evaluated using post-
prostatectomy prostate histology. 
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1.6 Outline of this thesis 
1.6.1 Chapter 2: Magnetic resonance imaging-targeted, 3D 
transrectal ultrasound-guided fusion biopsy for prostate 
cancer: Quantifying the impact of needle delivery error on 
diagnosis 
Magnetic resonance imaging (MRI)-targeted, 3D transrectal ultrasound (TRUS)-
guided “fusion” prostate biopsy aims to reduce the 21–47% false negative rate of clinical 
2D TRUS-guided sextant biopsy, but still has a substantial false negative rate.  This could 
be improved via biopsy needle target optimization, by accounting for uncertainties due to 
guidance system errors, image registration errors, and irregular tumour shapes. This 
chapter takes an initial step toward the broader goal of improved prostate biopsy 
targeting.  In particular, it elucidates the impact of biopsy needle delivery error on the 
probability of obtaining a tumour sample as determined by suspicious lesions contoured 
by radiologists on MRI.  
Prior to this work, there had been only one study providing insight into a potential 
avenue for further improvement of the positive core rate of fusion biopsy84.  The authors 
of that work estimated the maximum allowable target registration error (TRE) of MRI-3D 
TRUS registration for correct grading of 95% of ADC-determined high Gleason grade 
tumour components of peripheral zone PCa with fusion biopsy of sphere-shaped tumours.  
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However, another perspective is that for a fusion biopsy system with a given needle 
delivery error, some (larger) tumours can be sampled with a clinically desired probability 
(e.g., 95%) in a single biopsy core and other (smaller) tumours will require more than one 
attempt in order to achieve the clinically desired probability of sampling the tumour in at 
least one of the cores taken.  This latter perspective is the one taken throughout this 
thesis. 
In this chapter, I estimated the probability of obtaining a positive tumour sample 
from 81 3D suspicious regions contoured on MRI by experts, in a single biopsy core. The 
findings from this work were critical for the justification of development of the biopsy 
simulation software platform which allowed the simulation of multiple biopsy attempts 
and different targeting schemes for each lesion, as discussed in Chapter 3. 
 
1.6.2 Chapter 3: A comparison of prostate tumour targeting 
strategies using magnetic resonance imaging-targeted, 
transrectal ultrasound-guided fusion biopsy 
In Chapter 2, it was determined that for a fusion biopsy system with a given 
needle delivery error, some larger tumours can be sampled with a clinically desired 
probability (e.g. 95%) in a single biopsy core, and other smaller tumours will require 
more than one targeted core to achieve the clinically desired probability of sampling the 
tumour in at least one of the cores taken. The rationale for this perspective is that in 
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principle, the positive yield of contemporary fusion biopsy systems can be increased by 
optimizing the number and within-tumour placement of targets for each tumour, with 
consideration given to taking a reasonable number of cores in a practical biopsy scenario. 
The previous study was intended as a preliminary step toward the overarching 
goal of increasing the positive yield of fusion prostate biopsy systems, and therefore 
experiments were built on a set of assumptions that must be relaxed to more accurately 
reflect the uncertainties involved in a fusion biopsy procedure. The previous error model 
assumed an overall needle delivery error that was isotropic and contained no systematic 
components. However, both systematic and random errors have been measured in fusion 
biopsy systems, and it is reasonable to consider that such errors could be present in any 
percutaneous needle delivery device. It is the purpose of the work in this chapter to relax 
these assumptions, and investigate the effects of this more complex error model on 
predicted tumour sampling probabilities. For the purpose of the experiments performed in 
this chapter, I developed a generalizable biopsy simulation software platform which 
allows repeated simulations of biopsy attempts on tumour segmentations, given the 
desired targeting strategy and an error distribution used to model the needle delivery error 
of any given fusion biopsy system.  A detailed description of the simulator algorithm is 
provided in Section 3.2.4. 
In this chapter, a “ring” targeting strategy was investigated, with the intention of 
compensating for a systematic error of known magnitude, but unknown direction. While 
this paper represents a step toward improving the manner in which lesions are targeted 
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using fusion biopsy, a prospective trial will ultimately be needed to determine the 
improvement in positive yield achieved through optimization of needle target selection. 
The data presented in this paper could potentially be incorporated into an onboard 
software module that provides automatic selection of biopsy target locations given the 
error characteristics of any particular biopsy system. 
 
1.6.3 Chapter 4: Investigating the impact of prostate biopsy 
needle delivery error on pathologic cancer risk assessment 
An important limitation of the studies described in Chapters 2 and 3 is that MRI-
defined regions of suspicion were used as biopsy simulation targets, without histologic 
confirmation of the core involvements and high-grade cancer yield resulting from biopsy 
simulation. In the work presented in Chapter 4, I addressed this issue by using 
histologically confirmed PCa tumours as contoured on digital histology images by 
genitourinary pathologists to conduct biopsy simulations and report core involvement and 
high-grade cancer yield as a function of biopsy system error. By using histology image 
contours to define tumour targeting, this work modeled idealized tumour targeting, 
wherein boundary delineation on the planning image is exactly concordant with lesions 
on histopathology.  
Although the use of histology imaging for simulated biopsy affords the ability to 
characterize percent core involvement and distribution of cancer grades in the core using 
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a recognized gold standard, due to clinical limitations histology images are 2D, sliced 
approximately in the axial orientation, and acquired sparsely throughout the midgland. 
Thus, the findings of this study were made under the assumption that apparent prostate 
tumour size and shape are invariant to tissue slicing orientation.   
This study provides a precursor to the ongoing work in the project, described in 
Section 5.4.  In this continuing work, my biopsy simulation platform will be used to 
determine how the biopsy needle delivery errors and targeting schemes discussed in this 
thesis affect tumour sampling probabilities when radiologist-defined contours on MR are 
used to select biopsy target locations, while co-registered whole-mount histopathology is 
used to confirm the contents of the simulated biopsy cores. 
 
1.6.4 Chapter 5: Conclusions and Future Work 
This chapter is dedicated to the overall conclusions of the major chapters in this 
thesis, while providing speculation for future work that could address remaining 
challenges stemming from this project. 
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Chapter 2 
 
2 Magnetic resonance imaging-targeted, 3D transrectal 
ultrasound-guided fusion biopsy for prostate cancer: 
quantifying the impact of needle delivery error on diagnosis* 
 
2.1 Introduction 
Prostate cancer (PCa) is the most common non-cutaneous cancer in North 
American men1,2.  The current clinical standard for PCa diagnosis is two-dimensional 
(2D) transrectal ultrasound (TRUS)-guided biopsy.  As PCa is seldom detectable on 
ultrasound, an extended sextant template is commonly used to guide 18-gauge core 
biopsy needles to extract 12 tissue samples (hereinafter referred to as cores) for 
microscopic examination by a pathologist to assess the presence and Gleason grade3 of 
cancer.  Methods have been proposed to optimize 2D TRUS-guided biopsy targeting 
strategy4,5.  However, these systematic approaches do not allow for biopsy target 
                                                 
*
This chapter has been previously published as P.R. Martin et al., “Magnetic resonance imaging-targeted, 
3D transrectal ultrasound-guided fusion biopsy for prostate cancer: quantifying the impact of needle 
delivery error on diagnosis,” Medical Physics 41(7), 073504 (2014). 
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optimization on a per-patient basis, and clinical biopsy has a false negative rate of up to 
23%6.  A negative biopsy in conjunction with a rising prostate-specific antigen (PSA) 
level measured on blood tests may precipitate referral for repeat biopsy to obtain positive 
confirmation of cancer, if present.  Additionally, 2D TRUS-guided biopsy may 
underestimate the Gleason score, which is related to the aggressiveness of the cancer.  A 
15-year clinical study involving 1670 men demonstrated that biopsy Gleason score was 
undergraded in 32% of the subjects, as compared to grading on radical prostatectomy 
specimens7.  Accurate biopsy needle targeting and guidance to obtain sufficient tumour 
tissue for reliable assessment of the presence and Gleason grade of cancer could reduce 
patient discomfort due to repeat biopsy and support the early diagnosis of prostate cancer 
while it remains small and curable. 
Futterer et al.8 showed that multiparametric magnetic resonance imaging (MRI) 
can support PCa detection and localisation, and has also been used for in-bore needle 
guidance9-13.  Emerging multiparametric MRI guidelines and scoring schemes14 are an 
important step forward in standardizing the interpretation of prostate MRI for definition 
of suitable targets for needle biopsy, and recommend the use of T2-weighted14,15 dynamic 
contrast-enhanced T1-weighted16,17, and diffusion weighted18,19 sequences. In addition, 
apparent diffusion coefficient maps derived from diffusion-weighted MRI have been 
shown to be predictive of Gleason grade20,21, raising the possibility of targeting biopsies 
only to regions suspicious for high-grade cancer on MRI. 
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3D TRUS-guided biopsy systems have been developed to improve upon the spatial 
information of 2D TRUS and allow for MRI targeting via image registration22-26. One 
such fusion biopsy system22 has shown improved positive core rates of 30.4% (compared 
to 7.1% for 2D TRUS) and 42.3% (compared to 25.6% for 2D TRUS)27 for moderate and 
high suspicion lesions, respectively, suggesting the value of MRI-targeted biopsy and 
motivating further optimization of this procedure.  In contrast to MRI, the use of TRUS 
for needle guidance has the advantage of low cost, widespread availability, real-time 
imaging, and compatibility with standard biopsy needles.  It is also compatible with the 
close access to the TRUS probe entry point required to accurately position biopsy 
needles, with patient positioning that is concordant with the usual training of the 
urologist.  Both approaches involve the registration of target regions delineated on 
diagnostic quality preprocedural multiparametric MRI with the needle guidance imaging 
(either TRUS or a rapidly acquired intra-procedural T2-weighted image on which 
tumours are poorly visualised), and a means for compensating for prostate motion during 
needle insertion.   
A recent study by van de Ven et al.28 provides insight into a potential avenue for 
further improvement of the positive core rate. The authors estimated the maximum 
allowable target registration error (TRE) of MRI-3D TRUS registration for correct 
grading of 95% of ADC-determined high Gleason grade tumour components of 
peripheral zone PCa with fusion biopsy of sphere-shaped tumours28. The results of that 
study lead to the observation that the positive core rate is related to the biopsy system 
error in delivering the needle to the intended tumour target (henceforth referred to as the 
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needle delivery error). Based on this observation, one point of view is that a fusion 
biopsy system must deliver needles to targets with no more than some maximum needle 
delivery error to provide a clinically useful positive core rate for all tumours of clinically 
significant sizes. Another perspective is that for a fusion biopsy system with a given 
needle delivery error, some (larger) tumours can be sampled with a clinically desired 
probability (e.g. 95%) in a single biopsy core, and other (smaller) tumours will require 
more than one attempt (i.e. more than one core targeted at the tumour at different time 
points during the procedure) in order to achieve the clinically desired probability of 
sampling the tumour in at least one of the cores taken. In principle, if we determine the 
number of core samples required for each tumour in a practical biopsy scenario (within a 
reasonable limit for the number of biopsy cores), we could increase the positive yield of 
contemporary fusion biopsy systems by optimizing the number and within-tumour 
placement of targets for each tumour.  
As a step toward optimization of prostate fusion biopsy targeting, the objective of 
this paper was to quantify the probability of obtaining a positive sample from MRI-
defined prostate tumours in one biopsy core, under the assumption that the physician 
aims for the optimal within-tumour needle target. Since prostate tumours are often 
irregularly shaped29, we made no assumptions regarding tumour shape and instead used 
the shapes of human prostate tumours as contoured by experts in 3D on MRI. We also 
investigated the effect of needle delivery error along the needle axis on the measured 
tumour burden as determined by percentage core involvement on the pathology report. 
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2.2 Materials and Methods  
2.2.1 Materials 
Images were retrospectively obtained from 49 patients (mean ± std age: 61.2 ± 7.5 
years) who were enrolled in prospective MRI-3D TRUS fusion prostate biopsy studies at 
our institution between February 2011 and July 2012. Inclusion criteria were: PSA > 4 
ng/mL, high clinical suspicion of PCa over prostatitis and no prior diagnosis of PCa. 
Multiparametric 3T MR images [T2-weighted, diffusion-weighted (from which an 
apparent diffusion coefficient map was calculated) and T1-weighted dynamic contrast 
enhanced] were collected from all patients using a Discovery MR750 (GE Healthcare, 
Waukesha, WI, USA) using an endorectal receive coil (Prostate eCoil, Medrad, Inc., 
Warrendale, PA, USA). On the day of MRI, a 3D TRUS image was acquired from each 
patient using an HDI-5000 ultrasound machine via tracked axial rotation22 of an end-
firing C9-5 5-9 MHz TRUS transducer probe (Philips Medical Systems, Seattle, WA, 
USA). 
 
2.2.2 Tumour contouring on MRI 
 All prostate MR images were prospectively reviewed in advance of biopsy by a 
radiologist & radiology resident each with 7 years of prostate MRI experience (including 
assessment of > 150 prostate MRI studies each) to identify any concerning lesions 
requiring MRI-TRUS fusion biopsy.  The concern for malignancy was assessed for each 
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lesion using information from all MR sequences, with particular attention paid to 
apparent diffusion coefficient (ADC) findings for lesions located within the peripheral 
zone.  81 lesions with indeterminate to high suspicion for malignancy were identified and 
selected for targeted biopsy.  All lesions were manually contoured in the coordinate 
system of the T2-weighted MRI that was used for MRI-3D TRUS fusion.  Although 
information from the ADC map was used to help determine the contour delineation, the 
ADC sequence was not used for fusion with 3D TRUS as the susceptibility of the 
diffusion imaging makes the ADC prostate prone to spatial distortion and therefore was 
not delineated as part of the original MRI-TRUS fusion biopsy study.  The boundaries of 
these regions were represented in 3D using triangle meshes and were registered into the 
3D TRUS context using an iterative closest point prostate surface based registration 
method30; point correspondence was established by mapping each point on the MRI 
prostate surface to the closest point (in terms of 3D Euclidean distance) on the 3D TRUS 
prostate surface. The registered triangle meshes were then rasterized to 3D binary images 
with voxel size <1 mm using the marching cubes algorithm31.  These meshes enclose 
volumes ranging from 0.18 cm3 to 5.22 cm3 (mean ± std volume: 0.81 ± 0.75 cm3).  
Table 2-1 shows the number of meshes with volumes in the range of 0 to 1 cm3, 1 to 2 
cm3, and ≥ 2 cm3 respectively. All subsequent calculations described in this paper were 
performed on these 3D binary meshes within the 3D TRUS spatial context.  In the 
description of the methods that follows, a positive tumour sample is defined as an 
instance where the centre point of the biopsy core intersects with the tumour region on 
the 3D binary image. 
51 
 
 
 
Table 2-1: Volume ranges of the contour meshes used in this study 
Volume range (cm3) Number of tumours 
0 < Volume < 1 61 
1 ≤ Volume < 2 16 
Volume ≥ 2 4 
 
2.2.3 Probability of positive tumour sampling for given needle 
delivery error 
To calculate the probability of obtaining a positive sample from each tumour with 
one biopsy attempt, we considered every point within the tumour region as a candidate 
target point, and used the 3D binary image of the tumour in conjunction with our error 
model to estimate the probability of obtaining a positive sample using each candidate 
target point. Specifically, we centred a 3D Gaussian (μ = [0,0,0] mm) distribution onto 
every candidate target point within each tumour. The standard deviation σ modeled the 
biopsy system’s root mean squared error (𝑅𝑀𝑆𝐸) (mm) in delivering a needle tip to a 
desired target location, with 𝜎 =
𝑅𝑀𝑆𝐸
√3
 as described by Hu et al.32. The probability of 
obtaining a tissue sample from each tumour was calculated by integrating the distribution 
function over the domain of the 3D tumour within its binary image. This procedure was 
repeated for each point within each tumour region as a candidate biopsy target, with the 
point of maximum probability 𝑃 selected as the optimal target. 𝑃 was calculated for each 
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tumour as a function of the overall root-mean-squared (RMS) error of the biopsy system 
and is defined as  
𝑃(𝜎, 𝑇) =  ∑ ∑ ∑ 𝐺𝜎(𝑖, 𝑗, 𝑘)  𝑠. 𝑡.  (𝑖, 𝑗, 𝑘) ∈ 𝑇
𝐿
𝑘=1
𝑁
𝑗=1
𝑀
𝑖=1 , 
where 𝐺 is the 3D array form of the zero-mean Gaussian distribution described above, of 
size 𝑀 ×𝑁 × 𝐿, and 𝑇 ∈  ℤ2 represents the domain defined by the contoured 3D 
suspicious region in the TRUS context.  
 
   
   
(A) (B) (C)    
Figure 2-1: (A) Three suspicious regions contoured on MRI, registered to 3D TRUS.  
(B) A Gaussian distribution centred onto the biopsy target point of a prostate tumour 
projection.  Note that a 2D tumour projection and 2D distribution are used for clarity of 
illustration; our calculations used 3D tumour volumes and 3D distributions. (C) A 
Gaussian distribution centred onto the biopsy target point of the same tumour from B, but 
modeled as a spheroid. 
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Previous work in this problem domain has been conducted under the assumption 
of spherical tumour shape28.  We measured the effect on 𝑃 of the assumption of spherical 
tumour shape by comparing the tumour sampling probabilities 𝑃 obtained without the 
spherical shape assumption to the corresponding values of 𝑃 obtained for spherical 
tumours of equivalent volumes to the 81 tumours in our data set.  For consistency with 
the method described in this section, we computed values of 𝑃 for spherical tumours 
using the same method on a 3D binary image representation of the sphere on the same 
digital grids as used for each of the 81 tumours in our data set (as opposed to computing 
them analytically).   
Lastly, we adapted our algorithm for calculating positive sampling probabilities in 
one biopsy attempt to provide the probability 𝑃2 of obtaining at least one positive sample 
when two biopsy cores are targeted to each tumour at the point of maximum probability.  
Probabilities were added using the properties of non-mutually exclusive events, wherein 
the probability of at least one positive sample in two biopsy attempts is 𝑃2 =
 𝑃(𝑓𝑖𝑟𝑠𝑡 𝑎𝑡𝑡𝑒𝑚𝑝𝑡)  +  𝑃(𝑠𝑒𝑐𝑜𝑛𝑑 𝑎𝑡𝑡𝑒𝑚𝑝𝑡) –  𝑃(𝑓𝑖𝑟𝑠𝑡 𝑎𝑛𝑑 𝑠𝑒𝑐𝑜𝑛𝑑 𝑎𝑡𝑡𝑒𝑚𝑝𝑡). 
 
2.2.4 Maximum needle delivery error for a given tumour 
sampling probability 
For each tumour in our sample, we estimated the maximum 𝑅𝑀𝑆𝐸 giving at least 
95% probability of a positive tumour sample in one biopsy core using the algorithm 
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described in the preceding section.  More precisely, we conducted an exhaustive search 
over a range of 𝑅𝑀𝑆𝐸 values from 0.5 mm to 7 mm in steps of 0.005 mm to 
find 𝑅𝑀𝑆𝐸′ = arg𝑚𝑎𝑥
𝑅𝑀𝑆𝐸
(𝑃(𝑅𝑀𝑆𝐸 √3⁄ , 𝑇) = 0.95). For the corresponding sphere of equal 
volume to each tumour, we estimated the same 𝑅𝑀𝑆𝐸 threshold using the method 
described by van de Ven et al.28.  To model the scenario where the physician aims for the 
centre of the tumour, for both the tumours and their corresponding spheres, the needle 
target was defined as the tumour centroid. We subtracted the maximum 𝑅𝑀𝑆𝐸 for each 
tumour from the corresponding maximum 𝑅𝑀𝑆𝐸 for its corresponding sphere to measure 
the effect of the spherical tumour shape assumption on the maximum acceptable (𝑃 ≥ 
95%) needle delivery error. 
To accommodate arbitrary tumour shapes, our approach is numeric, in contrast to 
the analytical approach taken by van de Ven et al.28. To measure the discrepancies 
introduced by our discretization of the calculations, for a range of spherical volumes and 
tumour sampling probabilities 𝑃, we conducted an exhaustive search to determine the 
maximum 𝑅𝑀𝑆𝐸 that would give at least 𝑃 probability of a positive tumour sample in 
one biopsy core for each value of spherical tumour volume.  This method is analogous to 
the calculation of the 𝑅𝑀𝑆𝐸 threshold as a function of hit rate and volume carried out by 
van de Ven et al.28. More precisely, for each probability value 𝑄 ∈
{0.50, 0.51,… ,0.98,0.99} (covering the same probability range as in the paper by van de 
Ven et al.28) and for binary volumes 𝑇𝑉 representing spherical tumours having volumes 
ranging from 0.02 mL to 2.0 mL in 0.02 mL increments, we calculated      𝜎𝑄,𝑉 =
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arg𝑚𝑎𝑥
𝜎
(𝑃(𝜎, 𝑇𝑉) = 𝑄) and the corresponding 𝑅𝑀𝑆𝐸 as 𝑅𝑀𝑆𝐸
𝑄,𝑉 = √3𝜎𝑄,𝑉.32  To 
further investigate the effect of spherical tumour shape assumption on predicted 
maximum allowable 𝑅𝑀𝑆𝐸, we carried out the same calculations of 𝑅𝑀𝑆𝐸 thresholds for 
the tumours in our data set without the assumption of spherical shape, for 𝑄 ∈
{0.50, 0.51,… ,0.98,0.99}. We also conducted an exhaustive search to determine the 
𝑅𝑀𝑆𝐸 value corresponding to 𝑃=95% (within 0.5% accuracy) for each tumour, using 
both methods.  We calculated the mean difference between methods, with the predicted 
RMSE values from the method in the paper by van de Ven et al.28 subtracted from the 
predicted RMSE values from our algorithm. 
 
2.2.5 Effect of axial error on measured tumour burden 
We investigated the effect of needle delivery error parallel to the ultrasound probe 
axis (henceforth axial error) on the measured tumour burden according to the percentage 
core involvement: the proportion of a core that contains tumour tissue. The interpretation 
of the percentage core involvement is a matter of current debate. We base the present 
exploration on the Johns Hopkins criteria, wherein a core involvement of ≥ 50% is 
interpreted to indicate a level of tumour burden warranting consideration of treatment 
beyond active surveillance33.  We performed a simulation to measure the effect of axial 
error on the measured tumour burden.  In particular, for the 55 tumours in our data set 
which should have a measured percentage core involvement of ≥ 50% if sampled ideally, 
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we measured the number of such tumours that would incorrectly have a measured 
percentage core involvement of < 50%, for a range of different values of axial error.   
We performed our simulation as follows.  The axial probe direction coincides 
with the 𝑧 axis in the image space of our 3D TRUS images.  Since the biopsy needle is 
oriented parallel to the ultrasound probe, the biopsy needle is also parallel to the 𝑧 axis.  
To simulate the extraction of a tissue core from a binary tumour image in this space, we 
positioned the needle laterally (along the directions orthogonal to the probe axis) by 
specifying its (𝑥, 𝑦) coordinates, and then specified a 𝑧 coordinate corresponding to the 
centre point of the biopsy core.  This needle positioning is shown in Fig. 2-2, with axis 
labels included.  We then considered only the image subdomain (𝑥, 𝑦, 𝑧 ±  9 𝑚𝑚), 
corresponding to an 18 mm core (as used in our biopsies) centred at (𝑥, 𝑦, 𝑧) and 
orthogonal to the (𝑥, 𝑦) plane.  For each binary tumour image 𝑇, 𝑥 and 𝑦 were set to the 
position corresponding to the thickest point of the tumour along the 𝑧 direction.  The 
absolute positive core length 𝐿(𝐴𝐸) was then computed to be the Euclidean distance 
between the two most mutually distant “on” pixels in 𝑇 within the biopsy core subdomain 
(𝑥, 𝑦, 𝑧 ±  9 𝑚𝑚), computed as a function of axial error (𝐴𝐸).  The percentage core 
involvement for an 18 mm core extracted from the ideal spatial location was then 
calculated as 𝐼(𝐴𝐸) = 𝐿(𝐴𝐸) 18𝑚𝑚⁄ × 100%.  For each tumour T we then found the 
minimum 𝐴𝐸 required to incorrectly obtain a percentage core involvement of < 50% as 
𝐴𝐸𝑚𝑖𝑛 =
arg𝑚𝑖𝑛
𝑎𝑏𝑠(𝐴𝐸)
 𝐼(𝐴𝐸) < 50%.  We performed this minimization by exhaustive search 
of values of 𝑧 from 0 mm to 15 mm in steps of 0.1 mm. 
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Figure 2-2: Simulated positioning of the biopsy needle at the centre of a tumour volume, 
with x, y and z directions defined. 
 
2.2.6 Estimation of biopsy system RMSE 
The approach presented in this work can in principle be applied to any biopsy 
system with a measured needle delivery error.  However, to provide context for our 
results, we calculated the needle delivery error of a contemporary fusion biopsy system 
developed at our institution22. Our clinical trial of this system involves several workflow 
steps, each contributing to needle delivery error. The RMS TREs of each step are 
enumerated as follows. (1) Pre-procedural MRI-3D TRUS and 3D TRUS-3D TRUS 
registrations to map MRI-defined tumour surfaces into the 3D TRUS context for 
targeting: 1.74 mm23 and 2.36 mm34, respectively. (2) Intra-procedural 2D-3D TRUS 
registration for prostate motion compensation during probe navigation and needle 
guidance: 1.63 mm35. (3) Needle guidance error of the biopsy system22: 1.0 mm. We 
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added these errors in quadrature under the assumptions that they are independent and the 
needle delivery error of the fusion biopsy system could be modeled using a Gaussian 
distribution. This yielded an estimated overall error in delivering a biopsy needle to an 
intended target to be 3.5 mm. 
 
2.3 Results 
2.3.1 Probability of positive tumour sampling for given needle 
delivery error 
The probability of a positive sample in one biopsy core, 𝑃, was calculated for 
each tumour, for 𝑅𝑀𝑆𝐸 = 1 mm through 6 mm.  This is shown in Fig. 2-3(A), where the 
81 points for every 𝑅𝑀𝑆𝐸 on the horizontal axis give the maximum probability of 
obtaining a positive sample from each tumour for each level of error.  For each 𝑅𝑀𝑆𝐸 
level on the horizontal axis, the probability on the vertical axis for tumour 𝑇 corresponds 
to 𝑃(𝜎, 𝑇), where 𝜎 =
𝑅𝑀𝑆𝐸
√3
. The red curve depicts the mean sampling probability for 
each value of 𝑅𝑀𝑆𝐸, and the broken black line depicts a 95% sampling probability.  For 
an 𝑅𝑀𝑆𝐸 of 3.5 mm (our system’s estimated needle delivery error) tumours with 𝑃 ≥
 95% had a mean ± std volume of 1.67 ± 1.01 cm3, with a maximum volume of 5.22 cm3 
and a minimum of 0.81 cm3, and those with 𝑃 <  95% had a mean ± std volume of 0.51 
± 0.21 cm3, with a maximum volume of 1.52 cm3 and a minimum of 0.18 cm3.  Both 
distributions of tumour volume (for 𝑃 ≥  95% and 𝑃 <  95%) passed a normality test; 
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with failure to reject the null hypothesis that the samples were drawn from normally 
distributed populations according to a one-sample Kolmogorov-Smirnov test (p > 0.05).  
The difference between these means was statistically significant according to a 
heteroscedastic two-tailed t-test (p < 0.0001).  This implies that despite the potential 
impact of differences in tumour shape on positive sampling probability, tumours with 
high (> 95%) probability of positive sampling can be distinguished from those with lower 
sampling probability based on tumour volume.  The upper bound of the 99% prediction 
interval for the tumour volumes with 𝑃 <  95% was 1.05 cm3; this inference provides 
some insight into the largest tumours that cannot be successfully sampled in one biopsy 
core with 95% confidence.  To explore the bias and confidence region for the differences 
between estimated tumour sampling probabilities with and without the spherical 
assumption, Fig. 2-4 shows a Bland-Altman plot of these differences at 𝑅𝑀𝑆𝐸 =  3.5 
mm; the observed positive bias is reflective of the overestimation of sampling probability 
resulting from the spherical assumption. Fig. 2-3(B) shows the differences in 
probabilities of a positive sample in one biopsy core arising from the use of the spherical 
assumption of tumour shapes, versus no spherical shape assumption.  The red curve 
depicts the mean difference for each value of 𝑅𝑀𝑆𝐸.  The use of the spherical tumour 
assumption results in a consistent overestimation of tumour sampling probability.  
However, the amount of overestimation varies with the RMSE of the biopsy system.  For 
instance, at 1.5 mm RMSE, the overestimation was relatively small, with mean ± SD of 
0.5±0.2% (range 0.0% to 1.9%).  At 4 mm RMSE, the overestimation was larger, with 
mean ± SD of 3.4±2.6% (range 0.0% to 15.4%).  The mean difference of the predicted 
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RMSE values from the van de Ven method, subtracted from the predicted RMSE values 
from our algorithm was -0.0046 mm, and the maximum difference observed was -0.075 
mm.  This implies that our algorithm under the assumption of spherical tumour shapes 
produces the same results as the algorithm used by van de Ven et al., to within 0.1 mm 
error. 
Fig. 2-5 shows the probabilities of obtaining at least one positive sample from 
each tumour when two biopsy attempts are made, targeted at the point of maximum 
probability, for 𝑅𝑀𝑆𝐸 = 1 mm through 6 mm. 
 
  
 
Figure 2-3: (A) Probability of obtaining a positive core sample for 81 3D tumours in one 
biopsy attempt, for RMSE from 1 to 6 mm. (B) Probabilities of a positive core sample in 
(A) with no spherical assumption, subtracted from the probabilities of a positive core 
sample under the spherical tumour assumption. Calculated for 81 3D tumours, for RMSE 
from 1 to 6 mm. 
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Figure 2-4: Plot of Bland-Altman analysis showing the differences between estimated 
tumour sampling probabilities with and without the spherical assumption, at RMSE = 3.5 
mm. 
 
Figure 2-5: Probability of obtaining at least one positive core sample for 81 3D tumours 
in two biopsy attempts, for RMSE from 1 to 6 mm. 
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2.3.2 Maximum needle delivery error for a given tumour 
sampling probability 
Fig. 2-6(A) shows the maximum 𝑅𝑀𝑆𝐸 such that a positive sample will be 
obtained from each tumour in one biopsy core, with no assumption of spherical shape. 
The distribution of predicted 𝑅𝑀𝑆𝐸 thresholds from Fig. 2-6(A) passed a normality test, 
and failed to reject the null hypothesis that the sample was drawn from a normally 
distributed population according to a one-sample Kolmogorov-Smirnov test (p > 0.05).  
The lower bound of the 95% prediction interval for the 𝑅𝑀𝑆𝐸 thresholds was 1.6 mm, 
and this inference provides some insight into the maximum needle delivery error such 
that 95% of tumours will be sampled in one biopsy core.  Fig. 2-6(B) indicates the 
differences in maximum 𝑅𝑀𝑆𝐸 estimated when making the assumption of spherical 
tumour shape, versus not making this assumption. The values on the horizontal axis show 
the maximum 𝑅𝑀𝑆𝐸 without the spherical assumption, minus the maximum 𝑅𝑀𝑆𝐸 with 
the spherical assumption. Negative values on the x axis indicate instances where making 
the assumption of spherical shape over-estimates the maximum allowable 𝑅𝑀𝑆𝐸 to 
achieve a 95% probability of sampling each tumour using a single biopsy core. Over-
estimation occurred in all but one tumour.  
 
 
63 
 
 
 
  
Figure 2-6: (A) Histogram of the maximum allowable RMSE values to achieve a 95% 
probability of sampling each tumour using a single biopsy core, predicted by our 
algorithm using no assumption of spherical tumour shapes. (B) Histogram of the 
differences obtained by subtracting the thresholds predicted under the assumption of 
spherical tumour shapes from the thresholds given in (A). 
 
Fig. 2-7 shows the RMS error threshold as a function of desired tumour sampling 
probability and tumour volume, under the assumption of spherical tumour shapes, 
calculated using our discrete approach.  The white numbers in black circles indicate the 2 
mm through 8 mm 𝑅𝑀𝑆𝐸 isocontours for spherical tumours.  Each row of small numbers 
of 2 mm through 8 mm corresponds to one of the 81 non-spherical tumours in our data 
set, having a volume corresponding to the position of this row on the vertical axis.  For 
instance, the row indicated by the shaded box corresponds to one tumour in our data set 
with a volume of 1.48 mL.  If the maximum permissible 𝑅𝑀𝑆𝐸s for sampling this non-
spherical tumour with each probability level 𝑄 agreed with those for a spherical tumour 
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of the same volume, then its 𝑅𝑀𝑆𝐸 integer transition points indicated by the small 
numbers 7 mm through 3 mm in this row would agree with the isocontours, as in the case 
of the 7 mm transition point beside the black star symbol near the bottom of the figure.  
However, the spherical assumption in this case resulted in an overestimation of the 
maximum permissible 𝑅𝑀𝑆𝐸.  For instance, under the spherical assumption, a system 
with a 5 mm 𝑅𝑀𝑆𝐸 would yield a sampling probability 𝑄 of 0.88 (solid vertical arrow), a 
9% overestimation of the 0.79 sampling probability estimated (dashed vertical arrow) 
when taking the non-spherical shape of the tumour into account.  This pattern of 
overestimation resulting from the spherical assumption is evident for most tumours in our 
data set (i.e. most of the numbers on the plot appear to the left of their corresponding 
isocontours).  The portion of Fig. 2-7 that is above the horizontal dotted line is similar to 
the plot which was published by van de Ven et al.28 using their analytical approach 
(Figure 2 in their article), demonstrating that our method can reproduce the results of that 
work in the context of our tests of the spherical tumour shape assumption in this paper.  
Due to space considerations, 4 outliers with volume > 2 mL were not included in this 
plot. 
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Figure 2-7: Plot showing the relationship between tumour volume V, sampling 
probability Q, and RMSEQ,V for spherical tumours (colour map and isocontour curves) 
and for the tumours in our data set without application of the spherical assumption (small 
digits rendered on the colour map).  Note the similarity of the colour map and isocontours 
above the horizontal dotted line to Figure 2 in the paper by van de Ven et al.28  See 
Section 2.3.2 for a detailed description of this figure. 
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2.3.3 Effect of axial error on measured tumour burden  
Fig. 2-8 shows the number of tumours (out of 55 in total) that would be 
misclassified as < 50% core involvement for each level of 𝐴𝐸𝑚𝑖𝑛 on the horizontal axis. 
No tumours are misclassified for 𝑅𝑀𝑆𝐸 ≤ 4 mm, and more than 50% of tumours are 
misclassified for 𝑅𝑀𝑆𝐸 ≥ 5.5 mm.  
 
Figure 2-8: Histogram of tumours incorrectly classified as < 50% core involvement due 
to axial error (AEmin) in biopsy needle delivery. 
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2.4 Discussion    
Context for the results of this paper was provided by a fusion biopsy system 
developed at our institution22 for which we estimated an overall needle guidance error of 
3.5 mm.  However, in principle, the contributions of this paper could be straightforwardly 
adapted to other fusion biopsy systems or to the MRI guidance context, provided that an 
estimate of the system’s needle guidance error is available. 
 
2.4.1 Probability of positive tumour sampling for given needle 
delivery error 
 Fig. 2-3(A) shows that for a 𝑅𝑀𝑆𝐸 of 3.5 mm, 𝑃 ≥  95% for 21 out of 81 
tumours, when the optimal target point (having largest 𝑃) was targeted by the needle. 
Therefore, more than one biopsy core must be taken from 74% of the tumours to achieve 
𝑃 ≥  95% for a biopsy system with an error of 3.5 mm.  Fig. 2-5 shows that for a 𝑅𝑀𝑆𝐸 
of 3.5 mm, 𝑃 ≥  95% for 68 out of 81 tumours when two biopsy attempts are made for 
each tumour and the optimal target point was used.  Thus the majority of tumours from 
our study can be sampled in two biopsy cores, with a probability of a 95% or greater.  Of 
the remaining 13 tumours, the largest observed tumour volume was 0.4 cc, suggesting 
that most tumours of clinically significant sizes36 could be sampled in two attempts on a 
system with 3.5 mm 𝑅𝑀𝑆𝐸.   
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The upper bound of the 99% prediction interval for volumes of tumours having 
𝑃 <  95% provides a useful rule of thumb that for a biopsy system with 3.5 mm RMS 
needle delivery error, one cannot expect to sample tumours of approximately 1 cm3 or 
smaller with 95% probability with only one biopsy core; multiple biopsy attempts should 
be made for such tumours at different time points during the procedure.  This rule of 
thumb incorporates the variability in tumour shapes represented in our data set.  To 
maximally increase the probability of achieving a positive sample, one would target 
different samples within the same lesion, all near to the point of maximum probability for 
the tumour target.  Doing so would require careful instruction, but this task is well within 
the capability of the trained operator with experience in sampling targets under TRUS 
guidance.  For smaller lesions, the use of MRI-guided biopsy could be considered as an 
alternative approach in centres where the necessary technologies are available. The 
superior soft tissue contrast on MRI and potential lesion visibility on the intra-procedural 
T2W images could potentially obviate the need to make more the one biopsy attempt in 
order to obtain a sample of smaller tumours.  Although this approach requires specialized 
hardware and longer procedure times (approximate 30-65 min/biopsy) on a modality that 
could result in substantial cost increases37-39, if this approach mitigated the need for 
additional biopsy sessions it could provide a cost reduction over the longer term.   
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2.4.2 Maximum needle delivery error for a given tumour 
sampling probability 
From Fig. 2-6(B) and Fig. 2-7, we observed that the spherical tumour shape 
assumption consistently overestimates the maximum allowable error to achieve a 95% 
tumour sampling probability. From a different perspective, given a fusion biopsy system 
error, the spherical tumour assumption may lead to an overestimation of positive tumour 
sampling probabilities. This is likely due to the irregular, non-spherical shapes of prostate 
tumours, with increasing deviation from sphericity further from 0 on the horizontal axis 
of Fig. 2-6(B).  However, the mean overestimation of tumour sampling probabilities 
under the assumption of spherical tumour shape was 3% for 𝑅𝑀𝑆𝐸 = 3.5 mm.  Therefore, 
assuming spherical tumour shape may be reasonable for many prostate tumours.  In Fig. 
2-3(B), there are 3 tumours which show a discrepancy in estimated positive sampling 
probabilities of more than 10% for at least one of the given 𝑅𝑀𝑆𝐸 values on the x-axis.  
The approximate locations of these three tumours within the prostate are right anterior 
midgland, right anterior apex and right peripheral zone apex respectively.  Sphericity 
measures were determined as the ratio of the surface area of a sphere with the same 
volume as the given tumour, to the surface area of the tumour.  These tumours have 
sphericity values of 0.793, 0.829 and 0.698 respectively. 
Based on the 95% prediction interval for the distribution in Fig. 2-6(A), we 
determined that a biopsy system would need to have a RMS needle delivery error of no 
more than 1.6 mm in order to sample 95% of tumours with one core.  Considering the 
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multiple sources of error contributing to needle delivery error in a guided biopsy system, 
it is reasonable to question the practicality of achieving this level of overall needle 
delivery error.  This observation motivates our perspective that some tumours of 
clinically significant sizes may require more than one biopsy attempt in order to be 
sampled during the first biopsy session. 
 
2.4.3 Effect of axial error on measured tumour burden  
The histogram shown in Fig. 2-8 indicates that for biopsy systems with needle 
delivery errors ≥ 4.5 mm, a steeply increasing proportion of patients who may need 
treatment (percentage core involvement ≥ 50%) could be misclassified as candidates for 
active surveillance (percentage core involvement < 50%). However, using a 
contemporary fusion biopsy system such as that developed at our institution27, with 3.5 
mm needle delivery error, none of the tumours in our sample would have been 
misclassified. Overall, the effect of axial error on measured tumour burden may be 
mitigated by the 18 mm core length for systems with sufficiently small needle guidance 
error, but this effect rapidly increases with increasing error. 
Although we have interpreted our results in the context of the Johns Hopkins 
criteria wherein a core involvement ≥ 50% precludes the use of active surveillance, it is 
important to note that the interpretation of the core involvement measure (specifically, 
how to measure the length of core involvement, and what threshold to use) is a matter of 
some controversy.  Current interpretation guidelines are based on the assumption that 
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samples were obtained from clinical standard 2D TRUS-guided biopsy, with its inherent 
sampling problems.  As accuracy of biopsy continues to increase with improved 
interpretation of MRI and other imaging modalities for targeting, and improved systems 
for image guidance of the biopsy needle (including both 3D TRUS and MRI guidance 
approaches) become available, it is reasonable to expect that for the overall population, 
the percentage of core involvement and also the percentage of cores involved may 
increase.  This will require a recalibration of the criteria for appropriate treatment 
selection based on these measures.  Thus, it could be valuable to revisit our results 
regarding percentage core involvement in the future as interpretation criteria continue to 
evolve. 
 
2.4.4 Limitations 
 The results of this work must be considered in the context of its strengths and 
limitations.  Although the simulations that we have conducted have relaxed the typically 
used assumption of spherical tumour shape and instead used the complex tumour shapes 
delineated in 3D by experts on MRI, the needle delivery error model is used subject to a 
set of assumptions that may be strong.  The use of a zero-mean 3D Gaussian distribution 
as the error model implies a lack of systematic error in any of the system components 
contributing to the overall needle delivery error.  However, it is reasonable to speculate 
that some sources of error may be systematic; e.g. image registration steps may be biased 
toward alignment of structures to edges apparent in the ultrasound images, which will 
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tend to be oriented orthogonally to the ultrasound beam direction.  Additionally, the use 
of this error model implies that needle delivery error is spatially isotropic, whereas it is 
reasonable to conjecture that needle delivery error may be spatially anisotropic, according 
to the physical constraints of needle insertion angle and considering the elongated nature 
of the biopsy core itself.  The empirical testing of these assumptions and characterization 
of each source of error in terms of bias and anisotropy in ongoing studies will provide 
information that will enhance our error model to more realistically reflect the practical 
biopsy situation.  Although the use of this simple error model constitutes a limitation of 
this work, controlling for this variable and keeping it consistent with previous work does 
allow for the specific measurement of the effect of the spherical tumour assumption in 
this work. 
Additionally, for our study on the effect of axial error on measured tumour 
burden, described in Section 2.2.5, we assumed that the thickest point of the tumour 
along the 𝑧-direction was hit by the simulated biopsy core, and investigated how error 
along the 𝑧-direction may affect the calculated percent core involvement.  However, this 
approach does not account for error in the 𝑥 and 𝑦 directions.  Therefore, this experiment 
represents a best-case scenario in terms of 𝑥 and 𝑦 error, and only investigates how error 
along the axial direction can affect measured tumour burden.  A further investigation on 
estimated core length in the presence of 𝑥,𝑦 and 𝑧 error is warranted.  
It should be noted that only contoured lesions selected for biopsy were included in 
this study, with no preference weighted toward lesions with imaging findings concerning 
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more aggressive tumour biology, such as those with low ADC values39.  Although 
contouring was done in the coordinate system of the T2W images, the ADC was assessed 
for tumour aggressiveness and this information was incorporated into the decision to 
target a lesion.  However, the tumour contouring performed for this paper was not 
intended to encompass only the highest-grade portions of the tumours.  In the context of 
prostate cancer diagnosis, it is of utmost importance not only to sample the cancer but 
also to characterize it, and in particular to obtain samples of tumours that are threatening 
to the patient (e.g. those containing Gleason grade 4 components).  A further study of our 
research question in the context of tumour contours focused only on aggressive cancer is 
warranted and would be valuable. Lastly, for small lesions with low ADC values, MRI-
guided biopsy could be considered as an alternative to 3D TRUS guidance in centres 
where the necessary technologies are available. 
 
2.5 Conclusions 
In this work, we estimated the probability of obtaining a positive tumour sample 
from 81 3D suspicious regions contoured on MRI by experts, in a single biopsy core. We 
observed that for a contemporary fusion biopsy system with 3.5 mm needle guidance 
error, one cannot expect to sample tumours with volume ≤ 1 cm3 with 95% probability in 
only a single attempt.  Our findings indicated that more than one core must be taken from 
the majority of tumours to achieve a sampling probability of 95% or greater for a biopsy 
system with an overall error ≥ 3.5 mm. In fact, we determined that a biopsy system 
74 
 
 
 
would need to have a RMS needle delivery error of no more than 1.6 mm in order to 
sample 95% of tumours in one core, with 𝑃 ≥ 95%.  This motivates our perspective that 
some tumours of clinically significant volume may require more than one biopsy attempt 
in order to be sampled during one biopsy session.  Due to the 18 mm core length, needle 
delivery error along the direction of the ultrasound probe axis may have little effect on 
the measured tumour burden when considering systems with sufficiently small needle 
guidance error (≤ 4 mm), but this effect rapidly increases with increasing error.  Lastly, 
we observed through comparison with a previously published method that the assumption 
of spherical tumour shape can lead to slight overestimation positive sampling 
probabilities.  Although this observation was significant (𝑝 < 0.05), the overestimation 
varied with biopsy system RMSE and the practical importance of this observation 
depends on both tumour asphericity and biopsy system needle delivery error.  This 
knowledge generation will support the development of an approach to optimized 
planning of within-tumour prostate biopsy targets which could support earlier diagnosis 
of PCa while it remains localized to the prostate and curable. 
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Chapter 3 
 
3 A comparison of prostate tumour targeting strategies using 
magnetic resonance imaging-targeted, transrectal ultrasound-
guided fusion biopsy* 
 
3.1 Introduction 
2D transrectal ultrasound (TRUS)-guided systematic biopsy is the current clinical 
standard for prostate cancer (PCa) diagnosis. However, as PCa is generally not detectable 
on ultrasound, a sextant or extended-sextant scheme is used to guide the biopsy needle to 
extract 6 to 12 tissue samples (cores) for pathologist examination in order to assess the 
presence and Gleason grade1 of cancer. However, this approach has been shown to have a 
21–47% false negative rate and therefore many patients return to the clinic for repeat 
biopsies2,3. Additionally, this biopsy method may either underestimate or overestimate 
the true Gleason score of a patient’s cancer4. Furthermore, it has been shown that 25–
                                                 
*
 This chapter has been previously published as P.R. Martin et al., “A comparison of prostate tumour 
targeting strategies using magnetic resonance imaging-targeted, transrectal ultrasound-guided fusion 
biopsy,” Medical Physics 45(3), 1018-1028 (2018). 
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37% of men who are placed on active surveillance after receiving 2D TRUS-guided 
systematic biopsy are removed from surveillance to receive treatment within 5 years5,6. 
This may be due to underestimation of tumour grade on initial biopsy, interval changes in 
the tumour histology, and/or patients opting for definitive treatment. 
It has been shown that multiparametric MRI (mpMRI) is an effective tool for PCa 
detection and localization7. The development of 3D TRUS-guided biopsy systems allows 
for improved spatial information relative to 2D TRUS, and MRI targeting via image 
registration (Fig. 3-1). These systems also avoid the cost of in-bore MRI-guided biopsy 
and enable implementation in an office setting. A 3D TRUS biopsy system with MRI-3D 
TRUS fusion (“fusion biopsy”) has been shown to produce significantly higher (p < 0.01) 
positive biopsy core rates, mean Gleason scores and tumour volumes sampled, compared 
to 2D TRUS-guided 12-core systematic biopsy8. A systematic review was conducted by 
Valerio et al, collecting 14 papers which compared MRI-TRUS fusion targeted biopsy 
versus 2D TRUS-guided systematic biopsy. It was found that MRI-TRUS fusion biopsy 
detected more clinically significant cancers using fewer cores compared with systematic 
biopsy (median 33%, range 13-50% for fusion biopsy; median 24%, range 5%-52% for 
systematic biopsy).  Fusion biopsy also led to the detection of some clinically significant 
cancers that would have been missed by standard biopsy alone (median 9%, range 5-
16%)9. Conversely, Tontilla et al.10 did not observe any significant improvement in terms 
of clinically significant cancer detection rate from the use of MRI-TRUS fusion targeted 
biopsy vs. the extended sextant standard for target selection. However, it is worth noting 
that of the three operating clinicians in their study (with 5, 10 and 15 years of 2D-TRUS 
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guided systematic prostate biopsy experience respectively), none had any prior 
experience with targeted biopsies. 
While this work focuses on MRI-TRUS fusion using image registration software, 
another approach to TRUS-guided biopsy of prostate MRI-defined lesions is “cognitive 
registration.” This approach involves intuitive visual alignment between MRI lesions and 
TRUS guidance11.  However, consensus has not yet been reached regarding the 
superiority of the cognitive vs. software fusion approaches. Two studies reporting that 
biopsy targeting of clinically significant MRI lesions using cognitive registration resulted 
in inferior cancer detection rates compared with MRI-TRUS fusion12,13, while another 
study found no significant difference in cancer detection rates between the two 
approaches14. Further investigation is warranted, as it may be that small but still clinical 
significant tumours may benefit more from MRI-TRUS fusion over cognitive 
registration, compared with larger tumours. 
Although fusion biopsy has generally shown increased positive core rates over 
traditional 2D-TRUS guided systematic biopsy, we believe there is further room for 
improvement of the method of target selection for this procedure. In particular, this 
biopsy targeting approach may be further improved by investigating the overall 
uncertainty in delivering a biopsy needle to intended point target locations within each 
3D contoured lesion. 
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Figure 3-1: (A) A red suspicious region contoured on MRI, registered to 3D TRUS.    
(B) An isotropic Gaussian distribution centreed onto the biopsy target point of a prostate 
tumour projection. Note that a 2D tumour projection and 2D distribution are used for 
clarity of illustration; our calculations used 3D tumour volumes and 3D distributions.   
(C) A Gaussian distribution with non-zero systematic error; hence it has been shifted off-
centre from the biopsy target point. 
 
There have been two recent studies that provide insight into potential avenues for 
improving the positive core rate of targeted prostate biopsy. The study by van de Ven et 
al.15 estimated the maximum target registration error allowed from MRI-3D TRUS 
registration for correct Gleason grading of 95% of peripheral zone PCa with fusion 
biopsy, assuming sphere-shaped tumours. Furthermore, our previous study using 
radiologist-contoured lesions16 determined that for a fusion biopsy system with a given 
needle delivery error, some larger tumours can be sampled with a clinically desired 
probability (e.g. 95%) in a single biopsy core, and other smaller tumours will require 
more than one targeted core to achieve the clinically desired probability of sampling the 
tumour in at least one of the cores taken. The rationale for this perspective is that in 
principle, the positive yield of contemporary fusion biopsy systems can be increased by 
A B C
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optimizing the number and within-tumour placement of targets for each tumour, with 
consideration given to taking a reasonable number of cores in a practical biopsy scenario. 
In our previous work16 and in this work, we have made no assumptions on tumour shape 
and instead used the shapes of human prostate tumours as contoured by expert readers in 
3D using MRI.  
Our previous study was intended as a preliminary step toward our goal of 
increasing the positive yield of fusion prostate biopsy systems, and therefore our 
experiments were built on a set of assumptions that must be relaxed to more accurately 
reflect the uncertainties involved in a fusion biopsy procedure. Our previous error model 
assumed an overall needle delivery error that was isotropic and contained no systematic 
components. However, both systematic and random errors have been measured in our 
fusion biopsy system17, and it is reasonable to consider that such errors could be present 
in any percutaneous needle delivery device. It is the purpose of this work to relax these 
assumptions, and investigate the effects of this more complex error model on predicted 
tumour sampling probabilities. Also, in our previous work16, we investigated the effect of 
needle delivery error along the needle axis (henceforth referred to as the axial direction) 
on the measured tumour burden as determined by percentage core involvement on the 
pathology report. However, this approach only considered error in the axial direction, and 
not in either the lateral or elevational directions when estimating the percent core 
involvement obtained. Therefore, in this work, we investigated the effect of 3D needle 
delivery error on the probability of successfully sampling a tumour and of obtaining a 
desired percent core involvement for each biopsy attempt. Lastly, in our previous work 
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we modeled the tumour centroid as the needle target location for all biopsy attempts. In 
this work, we investigate a new targeting strategy, henceforth referred to as “ring” 
targeting, with the intent of compensating for systematic error present in biopsy systems. 
This targeting strategy is discussed in Section 2.2.3. 
Of the sources of error discussed in our previous work, we suspect image 
registration between preprocedural and intraprocedural imaging to be a substantial 
contributor to systematic error in biopsy needle placement.  A 3D nonrigid MR-TRUS 
registration method was shown to have a median whole gland target registration error 
(TRE) of 1.76 mm (range 0.5 – 3.25 mm)18, while an intersession 3D TRUS-3D TRUS 
registration method has been shown to have an average whole gland TRE of 2.15 mm 
(range 0.3 – 5.9 mm)17.  In this work, we considered systematic errors ≤ 6 mm to 
practically achievable for clinically available MRI-TRUS fusion biopsy systems. 
We investigated the following research questions in this chapter. (1) For 
practically achievable random and systematic error magnitudes associated with fusion 
biopsy, in what instances does a ring targeting strategy provide a higher probability of 
obtaining cancer-positive biopsy sample compared to centroid targeting, and vice-versa? 
(2) In what instances does a ring targeting strategy provide a higher probability of 
obtaining a 50% core involvement from select tumours compared to centroid targeting, 
and vice-versa? 
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3.2 Materials and Methods  
3.2.1 Materials 
3.2.1.1 Patient characteristics 
The study was approved by the research ethics board of our institution, and 
written informed consent was obtained from all patients prior to enrolment. Images were 
obtained from 49 patients (mean ± std age: 61.2 ± 7.5 years). Inclusion criteria were: 
PSA > 4 ng/mL, high clinical suspicion of PCa over prostatitis, and no prior diagnosis of 
PCa. 
 
3.2.1.2 Imaging 
3 Tesla mpMR images (T2W, diffusion weighted and T1W dynamic contrast 
enhanced) were collected from the patients using a Discovery MR750 (GE Healthcare, 
Waukesha, WI, USA) with an endorectal coil (Prostate eCoil, Medrad, Inc., Warrendale, 
PA, USA). On the day of MR imaging, a 3D TRUS image was acquired from each 
patient using an HDI-5000 ultrasound machine via tracked axial rotation19 of an end-
firing C9-5 5–9 MHz TRUS transducer probe (Philips Medical Systems, Seattle, WA, 
USA). 
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3.2.2 Tumour contouring on MRI 
 All prostate mpMR images were reviewed prior to biopsy by a radiologist (C.R.) 
and radiology resident (D.C.) to identify any suspicious lesions requiring MRI-TRUS 
fusion biopsy. Both had 7 years of prostate MRI experience, including assessment of 
more than 150 prostate MRI studies each. All lesions were manually contoured in the 
coordinate system of the T2-weighted MRI that was used for MRI-3D TRUS fusion. 
However, the concern for malignancy was assessed using information from all MR 
sequences. Particular attention was paid to apparent diffusion coefficient (ADC) findings 
for lesions located within the peripheral zone. 81 lesions with indeterminate to high 
suspicion for malignancy were selected for targeted fusion biopsy. Although information 
from the ADC map was used to help determine the contour delineation, the ADC 
sequence was not used for fusion with 3D TRUS. This is due to the susceptibility of the 
diffusion imaging, which makes the ADC map prone to spatial distortion and therefore 
was not delineated as part of the original MRI-TRUS fusion biopsy study. 
The boundaries of these regions were represented in 3D using triangle meshes and 
were registered into the 3D TRUS context using an iterative closest point prostate surface 
based registration method20; point correspondence was established by mapping each point 
on the MRI prostate surface to the closest point (in terms of 3D Euclidean distance) on 
the 3D TRUS prostate surface. The registered triangle meshes were then rasterized to 3D 
binary images with voxel size <1 mm. These binary images enclose volumes ranging 
from 0.18 cm3 to 5.22 cm3 (mean ± std volume: 0.81 ± 0.75 cm3). These volumes were 
split into 3 groups, referred to as small tumours (volume < 0.5 cm3), medium tumours 
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(0.5 cm3 < volume < 1 cm3) and large tumours (volume > 1 cm3). Table 3-1 shows the 
descriptive statistics of tumour sizes for the small, medium and large tumour groups. The 
maximum diameter in the lateral-elevational plane was also measured for each tumour, 
and the mean values for each tumour group are reported in Table 3-1 (denoted as mean L-
E maximum diameter). All subsequent calculations described in this paper were 
performed on these 3D binary images within the 3D TRUS spatial context. In the 
description of the methods that follows, a positive tumour sample is defined as an 
instance where some portion of the 18 mm long standard biopsy needle core intersects 
with the tumour region on the 3D binary image. 
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Table 3-1: Descriptive statistics of tumour sizes in the three volume groups used in this 
study. 
 Small tumours 
(Vol ≤ 0.5 cm3) 
Medium tumours 
(0.5 cm3 < Vol < 1 
cm3) 
Large tumours 
(Vol ≥ 1 cm3) 
N 35 26 20 
Mean volume  
± Standard 
deviation (cm3) 
0.39 ± 0.089 0.66 ± 0.11 1.76 ± 1.02 
Max volume (cm3) 0.50 0.91 5.22 
Min volume (cm3) 0.18 0.51 1.01 
Mean L-E 
maximum diameter 
± Standard 
deviation (cm) 
 
1.09 ± 0.17 
 
1.35 ± 0.16 
 
1.99 ± 0.38 
Max L-E maximum 
diameter (cm) 
1.50 1.79 2.82 
Min L-E maximum 
diameter (cm) 
0.78 1.10 1.46 
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3.2.3 Targeting strategies 
 All simulations for this work were conducted using one of two targeting 
strategies, described in the following paragraphs. 
We tested the centroid targeting strategy (Fig. 3-2A), wherein we simulated 
targeting the centroid of the tumours for each biopsy attempt. We expected that this 
approach would produce the best results for simulations with an absence of systematic 
error. 
We also tested a “ring” targeting strategy (Fig. 3-2B) for all simulations that 
included a non-zero systematic error. In this approach, all targets were selected 
surrounding the tumour in the lateral-elevational plane, separated by equal arc length 
around a circle of radius SystMag, concentric to the tumour centroid (Fig. 3-2B), where 
SystMag is the systematic error magnitude. We selected the first target at a distance of 
SystMag from the tumour centroid. This target was selected at a random angle 𝜃 (0 ≤
𝜃 < 2𝜋) as measured from patient right. We expected that this approach would produce 
better results relative to the centroid targeting scheme in the presence of a non-zero 
systematic error. 
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Figure 3-2: (A) In the centroid targeting strategy, we modeled the tumour centroid as the 
biopsy target for each attempt. (B) In the ring targeting strategy, we modeled the target 
locations on a ring in the lateral-elevational plane (shown as L-E above). The ring was 
centred on the tumour centroid, and its radius was equal to the magnitude of systematic 
error in the lateral-elevational plane. Targets were spaced at equal arc lengths on the ring. 
This example shows 3 biopsy attempts. 
  
Figure 3-3 shows the software interface of a 3D MRI-TRUS fusion biopsy 
system19, illustrating the biopsy needle in relation to the prostate and two fused MR-
defined lesions in both 2D and 3D.  The real-time display of 3D fusion biopsy systems 
such as this one would allow easy incorporation of the two targeting strategies discussed 
in this section. 
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Figure 3-3: The software interface of a 3D MR-TRUS fusion biopsy system. 
 
3.2.4 Description of simulation algorithm 
Targets 𝑡 were selected as described in Section 3.2.3, where the set of targets is 
denoted T ⊂ ℝ3. The isotropic standard deviation 𝜎 of the Gaussian distribution modeled 
the biopsy system’s root mean squared needle delivery error (henceforth referred to as 
RMSE), where RMSE = |𝜎|. The mean of the Gaussian distribution 𝑔 was determined by   
𝑆𝑦𝑠𝑡𝑂𝑓𝑓𝑠𝑒𝑡 =
(
 
 
 
 
√
2
3
∗ 𝑆𝑦𝑠𝑡𝑀𝑎𝑔 ∗ cos (𝑆𝑦𝑠𝑡𝐴𝑛𝑔𝑙𝑒),
√
2
3
∗ 𝑆𝑦𝑠𝑡𝑀𝑎𝑔 ∗ sin(𝑆𝑦𝑠𝑡𝐴𝑛𝑔𝑙𝑒) ,
√
1
3
∗ 𝑆𝑦𝑠𝑡𝑀𝑎𝑔
)
 
 
 
 
 ,   (1) 
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where SystAngle is the angle of the systematic error ∈ [0,2𝜋] as measured from the 
lateral direction (Fig. 3-2) and SystMag is the magnitude of the systematic error. This 
distribution was centred onto each biopsy target, and  
𝑔:ℝ3 × 𝑇 × ℝ3 ×ℝ3 → ℝ,  
𝑔(𝑥, 𝑡, 𝑆𝑦𝑠𝑡𝑂𝑓𝑓𝑠𝑒𝑡, ∑)  =  
1
√|∑|(2𝜋)3
𝑒−
1
2
((𝑥+𝑡)−𝑆𝑦𝑠𝑡𝑂𝑓𝑓𝑠𝑒𝑡)(∑)−1((𝑥+𝑡)−𝑆𝑦𝑠𝑡𝑂𝑓𝑓𝑠𝑒𝑡)
′
,  (2)  
where 𝑥 = [𝑥1, 𝑥2, 𝑥3] represents the spatial coordinates of the distribution and 
∑ = [
|𝜎|2 0 0
0 |𝜎|2 0
0 0 |𝜎|2
] . 
The set S contains the points sampled from the Gaussian distribution, each point 
representing the resultant location of the centre of the biopsy cores after firing the needle 
at a target, where 
𝑠: 𝐺 → ℝ3, and  
𝑠(𝑔) = randomly sampled point from Gaussian distribution 𝑔 using the accept-reject 
Monte Carlo sampling method21. 
The set of lesions, 𝐿 is represented by 3D binary images defined within the domain Ω 
where 1s indicate tumour tissue, i.e. Ω ⊂ ℤ3 and 
𝑙: Ω → {0,1}.  
Next, function 𝑝 determined whether the desired core involvement, 𝑐 was achieved for 
each biopsy attempt, as follows 
𝑝: 𝑆 × 𝐿 × ℝ+ → {0,1} and 
𝑝(𝑠, 𝑙, 𝑐) =  {
1 𝑖𝑓 𝑠𝑎𝑚𝑝𝑙𝑖𝑛𝑔 𝑙𝑒𝑠𝑖𝑜𝑛 𝑙 𝑎𝑡 𝑝𝑜𝑖𝑛𝑡 𝑠 𝑦𝑖𝑒𝑙𝑑𝑠 𝑐𝑜𝑟𝑒 𝑖𝑛𝑣𝑜𝑙𝑣𝑒𝑚𝑒𝑛𝑡 ≥ 𝑐
0 𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒
.    (3) 
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We then defined the function “any core positive,” 𝑎𝑐𝑝(𝑇, 𝑙, 𝑆𝑦𝑠𝑡𝑂𝑓𝑓𝑠𝑒𝑡, 𝑅𝑀𝑆𝐸) = {0,1} 
to determine whether core involvement ≥ 𝑐 was achieved for any of the biopsy targets 
contained within set T, as described by the following algorithm. 
𝑃 = { } 
𝑓𝑜𝑟 𝑖 = 1 𝑡𝑜 |𝑇| 
  𝑃 = {𝑃 𝑝(𝑠(𝑔(𝑡𝑖, 𝑆𝑦𝑠𝑡𝑂𝑓𝑓𝑠𝑒𝑡, 𝑅𝑀𝑆𝐸)), 𝑙, 𝑐)} 
𝑒𝑛𝑑 𝑓𝑜𝑟 
𝑖𝑓 ∃𝑝 ∈ 𝑃 == 1 𝑎𝑐𝑝 = 1, 𝑒𝑙𝑠𝑒 𝑎𝑐𝑝 = 0 
Finally, we repeated this simulation 1000 times per tumour, and the “positive core 
fraction” or PCF was evaluated as follows: 
𝑝𝑐𝑓: 𝑇 × 𝐿 × ℝ3 × ℝ3 → [0,1], where 
𝑝𝑐𝑓(𝑇, 𝑙, 𝑆𝑦𝑠𝑡𝑂𝑓𝑓𝑠𝑒𝑡, 𝑅𝑀𝑆𝐸) =  
1
1000
∑ 𝑎𝑐𝑝(𝑇, 𝑙, 𝑆𝑦𝑠𝑡𝑂𝑓𝑓𝑠𝑒𝑡, 𝑅𝑀𝑆𝐸)1000𝑠𝑖𝑚=1 .   (4) 
 
3.2.5 Investigating probability of obtaining a cancer-positive 
sample 
First, we investigated the positive core fraction obtained from each lesion with the 
goal of obtaining biopsy cores that contain some portion of the lesion tissue, i.e. core 
involvement > 0 (𝑐 > 0). We calculated PCF for all 81 lesions, for systematic error 
magnitude (SystMag) ranging from 1 to 6 mm, and RMSE ranging from 1 to 6 mm. We 
determined this for both ring and centroid targeting schemes with the number of targets 
|𝑇| ranging from 2 to 4. We then determined the median PCF across all tumours in the 
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small, medium and large groups respectively, for each systematic error magnitude and 
RMSE, and each number of biopsy targets under both targeting schemes. In order to 
account for varying lesion shapes, we then averaged each of these results over 4 
systematic error angles (SystAngle), 
𝜋
4
, 
3𝜋
4
, 
5𝜋
4
 and 
7𝜋
4
. 
 
3.2.6 Investigating probability of obtaining a 50% core 
involvement 
One common criterion for determining risk stratification for PCa patients is the 
measure of percent core involvement, or the proportion of the biopsy needle core that 
contains tumour tissue after obtaining a cancer-positive biopsy sample (in this work we 
assumed an 18 mm long needle core). Under current guidelines for PCa risk22,23, a 
patient’s cancer cannot be classified as very low risk when one or more cancer-positive 
samples are obtained with a ≥ 50% core involvement, even if all other conditions for 
very low risk disease are satisfied. Therefore, we repeated the process described in 
Section 3.2.5, but in order to determine the PCF values associated with obtaining a core 
involvement ≥ 50%. In this experiment, we only used the tumours in our study that were 
large enough in the axial direction to obtain such a core involvement. Table 3-2 shows 
the number of tumours in each volume group that are large enough to obtain a 50% core 
involvement.  
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Table 3-2: Number of tumours from each volume group large enough to obtain a 50% 
core involvement. 
Tumour volume group Number of tumours where ≥ 50% core 
involvement is possible 
Small (Vol < 0.5 cm3) 15 
Medium (0.5 cm3 ≤Vol < 1 cm3) 20 
Large (Vol ≥ 1 cm3) 20 
 
 
3.2.7 Comparing targeting strategies 
 Both the PCF associated with obtaining a cancer positive sample, and the PCF 
associated with obtaining a ≥ 50% core involvement were calculated for 2 to 4 biopsy 
attempts (|𝑇|), for both targeting strategies and for the small, medium and large tumour 
groups. The median PCF across all tumours in each group was calculated for each 
targeting strategy and for both systematic error magnitude (SystMag) and RMSE ranging 
from 1 to 6 mm. The median PCF observed for the centroid targeting strategy was then 
plotted alongside the median PCF observed using the ring targeting strategy. 
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3.3 Results 
3.3.1 Probability of a obtaining a cancer positive biopsy sample 
  Figure 3-4 shows the median PCF of obtaining biopsy cores with core 
involvement > 0 across all 81 tumours, for both the ring and centroid targeting strategies. 
Red boxes indicate situations where the ring targeting strategy yields a higher sampling 
probability, blue boxes indicate instances where centroid targeting has the higher 
probability, and green indicates no difference. Asterisks indicate a significant difference 
in sampling probabilities between both targeting strategies as determined by two-sided 
Wilcoxon signed rank test (p < 0.05). For instance, if we observe Fig. 3-4a, for a 
systematic error of 6 mm and a RMSE of 1 mm, ring targeting provides a tumour 
sampling probability of 73% while centroid targeting achieves a probability of 52%. 
Therefore, as 73% > 52%, this box is coloured red to indicate that ring targeting 
outperforms centroid targeting. Similarly, for a systematic error of 3 mm and RMSE of 6 
mm, ring targeting achieves a sampling probability of 74% while we observe a 76% 
probability under centroid targeting. As 74% < 76%, this box is coloured blue to indicate 
that centroid targeting outperforms the ring approach in this instance. 
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Figure 3-4: Median positive core fraction across all 81 tumours, obtained through ring 
targeting (R) and centroid targeting (C), given RMSE and systematic error magnitude in 
mm. Asterisks indicate significant differences (p<0.05). 
 
Fig. 3-5(A-C) highlights a situation where systematic error dominates over 
random error. These plots show the PCF achieved through both targeting strategies for 2, 
3 and 4 biopsy attempts in the situation where Systematic Error Magnitude = 6 mm and 
RMSE = 2 mm. Conversely, Fig. 3-5(D-F) shows a comparison between the PCF 
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achieved through both targeting strategies for 2, 3 and 4 biopsy attempts in the situation 
where Systematic Error Magnitude = 2 mm and RMSE = 6 mm. 
 
   
   
Figure 3-5: PCF achieved through ring targeting and centroid targeting for 2, 3 and 4 
biopsy attempts when a-c) Systematic Error Magnitude = 6 mm and RMSE = 2 mm and 
d-f) Systematic Error Magnitude = 2 mm and RMSE = 6 mm 
 
Lastly, Table 3-3 shows the maximum tumour sampling probability increases achieved 
through ring targeting over centroid targeting for each tumour volume group and for 2, 3 
and 4 biopsy attempts, followed by the maximum probability increases achieved through 
centroid targeting over the ring method.  
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Table 3-3: Trends observed in tumour sample PCF achieved through ring targeting 
versus centroid targeting. 
 
 
Maximum probability increase 
achieved by ring over centroid (%) 
Maximum probability increase 
achieved by centroid over ring (%) 
2 Attempts 21 4 1 3 3 2 
3 Attempts 33 4 0 2 3 1 
4 Attempts 32 2 0 2 2 1 
 Small 
tumours 
Medium 
tumours 
Large 
tumours 
Small 
tumours 
Medium 
tumours 
Large 
tumours 
 
3.3.2 Probability of obtaining a 50% core involvement 
Next, the median PCF of biopsy cores containing a 50% core involvement or 
greater was determined from the tumours in each group that were large enough (in the 
axial direction) to obtain such a core involvement (55 out of 81 tumours). Again, the 
median PCF across all 55 tumours was calculated for systematic error and RMSE ranging 
from 1 to 6 mm (Fig. 3-6). Red boxes indicate situations where the ring targeting strategy 
yields a higher sampling probability, blue indicates instances where centroid targeting has 
the higher probability, and green indicates no difference. Asterisks indicate a significant 
difference in sampling probabilities between both targeting strategies as determined by 
two-sided Wilcoxon signed rank test (p < 0.05). 
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Figure 3-6: Median 50% core involvement Positive Core Fraction across 55 tumours, 
obtained through both ring targeting (denoted “R”) and centroid targeting (denoted “C”), 
given RMSE and systematic error magnitude in mm. Asterisks indicate significant 
differences (p<0.05). 
 
Figure 3-7A-C shows a comparison between the 50% core involvement PCF 
achieved through both targeting strategies for 2, 3 and 4 biopsy attempts in the situation 
where Systematic Error Magnitude = 2 mm and RMSE = 6 mm. 
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Figure 3-7D-F shows a comparison between the PCF achieved through both 
targeting strategies for 2, 3 and 4 biopsy attempts in the situation where Systematic Error 
Magnitude = 2 mm and RMSE = 6 mm. 
 
   
   
Figure 3-7: PCF of 50% core involvement achieved through ring targeting and centroid 
targeting for 2, 3 and 4 biopsy attempts when A-C) Systematic Error Magnitude = 6 mm 
and RMSE = 2 mm and D-F)  Systematic Error Magnitude = 2 mm and RMSE = 6 mm. 
 
Similar to Table 3-3 in Section 3.4.1, Table 3-4 shows the maximum 50% core 
involvement probability increases achieved through ring targeting over centroid targeting 
for each tumour volume group and for 2, 3 and 4 biopsy attempts, followed by the 
maximum probability increases achieved through centroid targeting over the ring method.  
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Table 3-4: Trends observed in 50% core involvement PCF achieved through ring 
targeting versus centroid targeting. 
 Maximum probability increase 
achieved by ring over centroid (%) 
Maximum probability increase 
achieved by centroid over ring (%) 
2 Attempts 13 23 24 3 5 3 
3 Attempts 20 33 35 3 5 3 
4 Attempts 24 39 38 2 5 3 
 Small 
tumours 
Medium 
tumours 
Large 
tumours 
Small 
tumours 
Medium 
tumours 
Large 
tumours 
 
 
3.4 Discussion 
It has been demonstrated that targeted fusion biopsy shows an increase over 
systematic TRUS-guided biopsy in both cancer-positive core rate and clinically 
significant cancer detection rate among PCa patients8,14,24-28, samples more cancer per 
biopsy core for lesions of low, moderate and high suspicion for PCa29 and also shows an 
increase in the cancer detection rate of anterior lesions specifically26. However, to the 
best of our knowledge there exists a gap in research with regards to the effect of within-
lesion point targeting strategies coupled with the uncertainty in delivering a biopsy needle 
to intended target locations within each 3D contoured lesion. We believe this may 
partially explain the discordance between reported study results; while most studies show 
an improvement in cancer detection rates through fusion biopsy over standard extended 
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sextant biopsy, at least one study did not show any improvement10. Interestingly, it has 
also been shown that median prostate volume was significantly higher in patients with 
negative biopsy results after undergoing fusion biopsy24 and that the fusion biopsy cancer 
detection rates decrease with increasing prostate volume28, indicating that cancer-positive 
biopsy cores may be more difficult to obtain in patients with larger prostates under the 
current ad-hoc target selection methods used for fusion biopsies. 
We expanded on our previous work16 by including the presence of systematic 
error in our error model. Furthermore, we investigated a “ring” targeting strategy with the 
intention of compensating for a systematic error of known magnitude, but unknown 
direction. This allowed us to observe which biopsy system error characteristics lead to 
better performance under ring targeting, and which allow better performance under 
centroid targeting. 
 
3.4.1 Probability of obtaining a cancer positive biopsy sample 
We observed that for small tumours, ring targeting tends to outperform centroid 
targeting when systematic error magnitude dominates RMSE. This increase in probability 
becomes larger as we move from 2 to 3 biopsy attempts, but the amount of probability 
increase levels off between 3 and 4 biopsy attempts (Fig. 3-5a). For medium tumours, 
this effect is largely reduced. For large tumours, we see virtually no difference in 
sampling probabilities between the two targeting methods. We expect that this is because 
tumour sampling probabilities are so high in these instances for medium and large 
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tumours (PCF ≥ 83% for medium tumours when systematic error ≤ 6 mm and RMSE ≤
 3 mm, and PCF ≥ 98% for large tumours over the same error range), that room for 
improvement between targeting strategies is limited.  
When RMSE dominates over systematic error, we generally observed some very 
modest improvements in PCF (≤ 3%) achieved through centroid targeting over ring 
targeting for small and medium tumours. For large tumours, the difference was ≤ 2%. 
For small tumours, substantially larger probability increases were achieved 
through ring targeting over centroid as opposed to vice-versa. This trend was not 
observed for medium tumours where the largest difference in PCF between the centroid 
and ring targeting strategies was 4%, nor was it observed for large tumours where the 
greatest difference in PCF was 1%. 
 
3.4.2 Probability of obtaining a 50% core involvement 
We observed that when systematic error magnitude ≥ RMSE for small and 
medium tumours, ring targeting tends to outperform centroid targeting in terms of PCF of 
50% core involvement samples. However, for these small and medium tumours, as 
systematic error increases to 5 mm and above, this difference between PCF of ring and 
centroid targeting begins to approach 0. We expect this is because at this level of 
systematic error, the median probability of obtaining a 50% core involvement approaches 
0 for both targeting strategies.  
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We did not observe this same trend for the large tumour group, as these tumours 
are large enough such that PCF of 50% core involvement remains >30% for both 
targeting strategies and for all RMSE and systematic error magnitudes ≤ 6 mm. We 
observe that for large tumours, ring targeting tends to outperform centroid targeting when 
systematic error magnitude ≥ 4 mm and RMSE ≤ 2 mm. 
As in Section 3.4.1, we generally observed a very modest improvement through 
centroid targeting over ring targeting in 50% core involvement PCF (≤ 5%) for small, 
medium and large tumours when RMSE dominates over systematic error. Overall, 
substantially larger probability increases are achieved through ring targeting over 
centroid as opposed to vice-versa for small, medium and large tumours. 
 
3.4.3 Clinical relevance 
 The overall goal of this work was to determine translational lessons that can be 
quickly incorporated into the workflow of within-lesion target selection for fusion 
prostate biopsy. We envision that manufacturer-provided error estimates for any MRI 
targeted, 3D TRUS-guided fusion prostate biopsy system can be used in conjunction with 
our results in order to allow any physician performing a targeted biopsy to determine 
which targeting strategy should provide the higher probability of sampling the desired 
lesion. Therefore, this study highlights the need for manufacturers to provide detailed 
error information for their biopsy guidance systems, allowing operators to best use their 
systems.   
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We believe that additional targeting strategies can continue to be explored in this 
problem space, including perhaps a combination of centroid and ring targeting in 
instances where systematic error magnitude does not dominate over RMSE.  We also 
envision that fusion biopsy target locations can be considered in combination with 
“sextant” systematic biopsy core locations, such that small displacements could be made 
to existing sextant core locations in order to enable more targeted biopsy attempts with 
minimal increase in the total number of biopsy cores obtained. 
 While the core involvement measure investigated in this paper is important for 
prostate cancer burden estimation under current guidelines for estimating PCa risk22,23, 
these guidelines have been developed from the long term results of systematic biopsies.  
It is worth noting that as more accurate prostate biopsy methods become more widely 
available, these guidelines may change in order to adapt to new practices. 
While this paper represents a first step toward improving the manner in which 
lesions are targeted using fusion biopsy, a prospective trial will ultimately be needed to 
determine the improvement in positive yield achieved through optimization of needle 
target selection. The data presented in this paper could be incorporated into an onboard 
software module that provides automatic selection of biopsy target locations given the 
error characteristics of any particular biopsy system. Exploring this possibility is an 
ongoing focus of our current work. 
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3.4.4 Limitations 
The key limitation of this study is that we used suspicious lesions contoured by 
radiologists on mpMRI as surrogates for prostatic tumours. Therefore, the lessons taken 
from our results were reached under the assumption that the radiologist contoured lesions 
are reflective of true prostate tumour shapes.  However, it has been shown that these MR-
defined lesions are consistently smaller than the true tumour size as measured on post-
prostatectomy histology30.  Errors introduced in biopsy target selection from these MR-
defined lesions may have a substantial effect on cancer detection rates for MRI-TRUS 
fusion biopsy. Our ongoing work includes the use of digitized radical prostatectomy 
histology images that have been registered to mpMRI, allowing us to investigate this 
further. 
 It should be noted that only contoured lesions that were selected for targeted 
biopsy were included in this study, with no preference toward regions of high suspicion 
of aggressive tumour biology. However, while contouring was performed in the 
coordinate system of the T2W images, apparent diffusion coefficient (ADC) maps 
obtained from diffusion weighted MR were also assessed for tumour aggressiveness and 
this information was considered in deciding whether to target lesions.  
 
3.5 Conclusions 
In this work, we developed a biopsy simulator for determining biopsy sampling 
probabilities on 3D tumours in a 3D TRUS-guided fusion biopsy context. We expanded 
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on our previous work by including the presence of systematic error in our error model. 
Furthermore, we investigated a “ring” targeting strategy with the intention of 
compensating for a systematic error of known magnitude, but unknown direction. Our 
results suggest that the optimal targeting scheme for prostate biopsy depends on the 
relative levels of systematic and random errors in the system. Where systematic error 
dominates, a ring targeting scheme may yield improved probability of tumour sampling, 
particularly for small tumours. We envision that the data presented in this paper can be 
used to aid in target selection strategies for clinicians performing targeted prostate 
biopsies on any MRI targeted, 3D TRUS-guided biopsy system. 
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Chapter 4 
 
4 Investigating the impact of prostate biopsy needle delivery 
error on pathologic cancer risk assessment* 
 
4.1 Introduction 
2D transrectal ultrasound (TRUS)-guided biopsy is the clinical standard for 
prostate cancer (PCa) diagnosis. As PCa is often not detectable on ultrasound, a 
systematic extended-sextant targeting scheme is used for needle guidance, involving 6 to 
12 tissue samples (cores) obtained via biopsy. However, this procedure has a false 
negative rate of 21–47% and many patients require repeat biopsies1,2. Additionally, this 
biopsy method has been shown to misrepresent the true Gleason score of a patient’s 
cancer3. While augmented approaches for systematic template biopsy have been 
proposed4, multiparametric MRI (mpMRI) is an accepted tool for PCa detection and 
localization5,6, which allows for a targeted biopsy approach.  Therefore, MRI-targeted, 
3D TRUS-guided “fusion” biopsy systems have been developed to allow for magnetic 
                                                 
*
This chapter is adapted from the manuscript entitled “Investigating the impact of prostate biopsy guidance 
error on pathologic cancer risk assessment” by P.R. Martin et al., SPIE Journal of Medical Imaging (under 
review). 
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resonance imaging targeting via image registration.  One specific fusion biopsy system7 
has shown improved positive core rates of 30.4% (compared to 7.1% for 2D TRUS) and 
42.3% (compared to 25.6% for 2D TRUS) for moderate and highly suspicious lesions, 
respectively8.  Furthermore, a systematic review of 14 papers comparing fusion biopsy 
with 2D TRUS-guided systematic biopsy found that the use of fusion biopsy led to the 
detection of more clinically significant cancers using fewer biopsy cores when compared 
with 2D TRUS-guided systematic biopsy9.  There has been one study where the authors 
did not observe a significant increase in the clinically significant cancer detection rate 
when performing fusion biopsy compared with systematic biopsy; however, none of the 
three clinicians participating in this study (with 5, 10 and 15 years of 2D TRUS-guided 
systematic biopsy experience, respectively) had prior experience with performing 
targeted biopsies10.  
Although fusion biopsy has led to increased positive core rates, there may be 
further room for improvement of the method for target selection in this procedure. Our 
previous work showed that an improved positive core rate could be obtained by 
optimizing the number of samples taken from each target, according to lesion size and 
shape, and the error characteristics of the biopsy system11,12.  We showed that if one can 
determine the number of core samples required for each tumour in a practical biopsy 
scenario (within a reasonable limit for the number of biopsy cores), the positive yield of 
contemporary fusion biopsy systems could be increased by optimizing the number of 
biopsy attempts for each suspicious lesion. However, accurate characterization of a 
patient’s prostate cancer depends not only on the presence of cancer in the biopsy sample, 
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but critically also on the proportion of cancer contained in each biopsy core (referred to 
as the “percent core involvement”)13,14 and the presence of high-grade cancer in the cores. 
There is evidence of a relationship between the apparent diffusion coefficient (ADC) 
values on prostate MRI and Gleason grade15,16; suggesting a benefit to targeting biopsy 
using ADC to maximize the yield of high-grade cancer, if present. Previous work in this 
field has estimated the necessary biopsy accuracy for targeting regions of ADC maps 
suspected to harbor high-grade cancer17.  
Although strides have been made toward understanding how to optimize biopsy 
targeting in these previous studies11,12,17, an important limitation is that MRI-defined 
regions of suspicion were used as biopsy simulation targets, without histologic 
confirmation of the core involvements and high-grade cancer yield resulting from biopsy 
simulation. In this work, we address this by using histologically confirmed PCa tumours 
as contoured on digital histology images by genitourinary pathologists to conduct biopsy 
simulations and report core involvement and high-grade cancer yield as a function of 
biopsy system error. By using histology image contours to define tumour targeting, this 
work models idealized tumour targeting, wherein boundary delineation on the planning 
image is exactly concordant with lesions on histopathology. Results from our simulations 
thus represent a best-case scenario, since lesions contoured by experts on MRI are 
generally not volumetrically concordant with true histologic lesions18,19. As histology 
slices are inherently 2D and oriented approximately axially, our simulations were 
conducted in 2D under the assumption that prostate tumour size and shape are invariant 
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to slicing angle. This is a necessary compromise to reap the benefits of the enhanced core 
involvement and grade information provided by histology imaging, compared to MRI.  
We investigated the following research questions in this paper: (1) What is the 
relationship between needle delivery error and percent core involvement, for lesions of 
all Gleason grades, and for high-grade lesions?  (2) What is the relationship between 
needle delivery error and proportion of biopsy attempts that miss the target for lesions of 
all Gleason grades, and for high-grade lesions?  (3) What is the relationship between the 
number of biopsy attempts made on each tumour target, and the probability of 
successfully obtaining a tumour sample in at least one of the attempts? 
 
4.2 Materials 
4.2.1 Patient characteristics   
52 specimens were obtained after radical prostatectomy. Inclusion criteria: patient 
age ≥18 years, histologically confirmed clinical PCa stage T1 or T2, and ≥ 1 tumour 
focus with maximum diameter ≥ 5 mm. Exclusion criteria: prior PCa therapy, use of 5-
alpha reductase inhibitors within 6 months of study start, contrast agent allergy, sickle 
cell/other anemias, hip prosthesis, inability to comply with imaging, pelvic sources of 
artifacts, and MRI contraindications. 
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4.2.2 Digital histology imaging and contouring   
After standard whole-mount paraffin embedding, 4 𝜇m thick sections were cut 
from the prostate midgland and stained with hematoxylin and eosin. The slides were 
digitized at 0.5 𝜇m/pixel on a ScanScope GL (Aperio Technologies, Vista, CA) scanner. 
PCa was contoured by a physician trained in PCa morphology with contouring confirmed 
by a genitourinary pathologist (Fig. 4-1). PCa foci of different Gleason scores were 
differentiated from one another based on contour colour.  
 
Figure 4-1: Illustrating the level of detail used for histopathology contours in this study. 
G3 G4 G5 AtrophyPING3+4 G4+3 G5+4
20 mm
2 mm 500 m
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4.3 Methods 
4.3.1 Image preparation for simulation   
All contour masks were downsampled to a 30 𝜇m isotropic pixel size. We 
extracted regions containing cancer of all Gleason grades (Fig. 4-2B), and regions 
containing only high-grade cancer (Gleason 4+3 and above; Fig. 4-2C). Dilation and 
erosion with a 600 𝜇m square structuring element was performed on each mask to 
connect nearby foci, followed by hole filling (Fig. 4-2D). Resulting foci with maximum 
diameter ≥ 5 mm were retained (after applying a 1.047 linear correction to each diameter 
to adjust for shrinkage due to formalin fixation20). This captures all clinically significant 
tumours that may be plausibly visible on MRI. This yielded 307 foci of all Gleason 
grades, and 75 high grade foci.  Descriptive statistics of foci sizes for both groups are 
given in Table 4-1, where the diameter measure refers to the maximum length of each 
lesion. 
 
 
 
119 
 
 
 
   
  
Figure 4-2: (A) Image showing the prostate with contoured regions overlaid. (B) Binary 
image of showing cancer of all Gleason grades. (C)  High grade cancer only. (D) After 
defining overall foci from the fine-scale contours in Fig 4-2B; with a blue simulated 
biopsy core overlaid onto a red target tumour. Note that this core contains cancer from 
the targeted tumour, and also from the posterior tumour that was not targeted. 
A
10 mm 10 mm
B
10 mm
C D
10 mm
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Table 4-1: Descriptive statistics of foci sizes in all grade and high grade groups. 
 All grade lesions High grade lesions 
N 307 75 
Mean surface area  
± Standard deviation 
(mm2) 
68.6 ± 138.2 108.6 ± 234.0 
Max surface area (mm2) 1309.0 1309.0 
Min surface area (mm2) 5.6 5.9 
Mean diameter ± Standard 
deviation (mm)  
14.0 ± 9.1 
 
14.8 ± 12.1 
 
Max diameter (mm) 56.3 56.3 
Min diameter (mm) 5.1 5.3 
 
4.3.2 Biopsy simulation  
We modeled the biopsy system’s root mean squared needle delivery error 
(RMSE) using a 2D Gaussian distribution with 𝜇 =  [0,0] and an isotropic 2D 𝜎. The 
magnitude of 𝜎 modeled the RMSE in delivering the centre of the needle core to a target 
location.  All simulations were performed using our in-house biopsy simulation platform 
described in Chapter 3,12 adapted to run on the 2D histology images used in this study.  
For each simulation, the centroid of the tumour was chosen as the biopsy target and the 
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biopsy needle was oriented in the posteroanterior direction (approximating a transrectal 
approach). The simulated final location of the biopsy needle centre was determined by a 
random offset from the target, drawn from the Gaussian distribution corresponding to the 
chosen RMSE. The angle of the needle was held constant. The contents of the 18 mm 
long biopsy core were then recorded for each of 1000 simulations per target.   
 
4.3.3 Experiments 
We conducted three experiments to address the research questions (enumerated as 
in the Introduction).  
  (1)  Relationship of needle delivery error and percent core involvement: We 
simulated biopsy on the 307 tumour foci containing all Gleason grades, for RMSE = 1 to 
6 mm, with one biopsy attempt per tumour. For each tumour at each RMSE level, this 
yielded 1,000 core length values between 0 mm and 18 mm, representing the amount of 
cancer found in the simulated core. We subtracted the 5th percentile core length from the 
95th percentile core length to obtain a nonparametric measure of variability in core length 
across the 1,000 simulated biopsies (henceforth the 5–95 percentile core involvement 
range). We performed the same simulation on the 75 tumour foci containing only high-
grade cancer. 
  (2)  Relationship between needle delivery error and proportion of biopsy attempts 
that miss the target: We used the core involvement data obtained from Experiment 1 to 
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calculate the proportion of biopsy cores from each 1,000-simulation run that entirely 
missed each tumour (i.e., core involvement of 0 mm). This was performed for the group 
of tumours of all grades and the high-grade tumour group, for RMSE = 1 to 6 mm and 
one biopsy attempt per tumour. 
(3)  Relationship between the number of biopsy attempts and the probability of 
obtaining a tumour sample: We used the procedure described in Experiment 1 to 
simulate 1, 2, and 3 biopsy attempts on each of the lesions in the all-grade tumour group, 
as well as the high-grade only tumours. We calculated the proportion of the 1,000 
simulations per tumour that resulted in a cancer positive sample, for RMSE = 1 to 6 mm. 
 
4.4 Results 
4.4.1 Experiment 1 – Relationship of needle delivery error and 
percent core involvement   
Fig. 4-3A and 4-3B show the 5–95 percentile core involvement ranges as a 
function of RMSE for the groups of all Gleason grade lesions and high-grade lesions, 
respectively. All median 5–95 percentile core involvement values in Fig. 4-3A are 
significantly different from each other (p < 0.05; Wilcoxon signed rank test).  
Furthermore, all medians in Fig. 4-3B are significantly different from each other (p < 
0.05; Wilcoxon signed rank test).  Significant differences were also detected between the 
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5–95 percentile core involvement values for lesions of all grades (Fig. 4-3A) and high-
grade lesions (Fig. 4-3B) at corresponding RMSE values when RMSE ≥ 4 mm (p < 0.05; 
Wilcoxon rank sum test); the median 5–95 percentile core involvement values were 
higher for high-grade lesions.  When RMSE ≤ 3 mm, there were no significant 
differences observed between lesions of all grades and high grade lesions (p > 0.05; 
Wilcoxon rank sum test).   For Fig. 4-3A, Pearson correlation coefficients showed a 
positive correlation (0.15 ≤ σ ≤ 0.44, p < 0.05) between the 5–95 percentile core 
involvement and tumour diameter for RMSE ≥ 4 mm, with no significant correlations for 
RMSE ≤ 3 mm. For Fig. 4-3B, we observed a significant positive Pearson correlation 
(0.25 ≤ σ ≤ 0.40, p < 0.05) between the 5–95 percentile core involvement and tumour 
diameter for RMSE ≥ 5 mm, with no significant correlations for RMSE ≤ 4 mm. 
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Figure 4-3: 95–5 percentile core involvement range values, for RMSE = 1 to 6 mm, 
calculated for (A) lesions of all Gleason grades and (B) high-grade lesions. Whiskers 
indicate the largest and smallest values within [median, median + (1.5 × inter-quartile 
range)] and [median – (1.5 × inter-quartile range), median] respectively, while red glyphs 
indicate outliers outside of this range. 
 
4.4.2 Experiment 2 – Relationship between needle delivery error 
and proportion of biopsy attempts that miss the target   
Figs. 4-4A and 4-4B show the proportion of tumour misses per 1,000 simulations 
as a function of RMSE for the group of all Gleason grade lesions and high-grade lesions, 
respectively. All median proportions of tumour misses in Fig. 4-4A are significantly 
different from each other (p < 0.05; Wilcoxon signed rank test). This is also true for the 
medians in Fig. 4-4B (p < 0.05; Wilcoxon signed rank test).  However, there were no 
significant differences detected between the proportions of tumour misses for all-grade 
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(Fig. 4-3A) and high-grade (Fig. 4-3B) lesions at corresponding RMSE levels (p > 0.05; 
Wilcoxon rank sum test).  For Fig. 4-4A, Pearson correlation coefficients showed a 
negative correlation (-0.63 < σ < -0.17, p < 0.05) between tumour diameter and 
proportion of missed biopsy attempts for all levels of RMSE.  For Fig. 4-4B, Pearson 
correlation coefficients showed a negative correlation (-0.65 < σ < -0.30, p < 0.05) 
between tumour diameter and proportion of missed biopsies for all levels of RMSE, with 
the exception of RMSE = 1 mm where no significant correlation was observed. 
 
  
Figure 4-4: The proportion of tumour misses per 1000 simulations calculated for (A) all 
Gleason grade and (B) high-grade lesions.  Whiskers indicate the largest and smallest 
values within [median, median + (1.5 × inter-quartile range)] and [median – (1.5 × inter-
quartile range), median] respectively, while red glyphs indicate outliers outside of this 
range. 
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4.4.3 Experiment 3 – Relationship between number of biopsy 
attempts and probability of a tumour sample 
Fig. 4-5 shows the percentages of cancer-positive cores as a function of RMSE, 
for 1–3 biopsy attempts.  Fig. 4-5A shows these results for 307 lesions of all Gleason 
grades, where the median percentages of positive tumour samples for one, two and three 
attempts are all significantly different (p < 0.05, Wilcoxon signed rank test).  Fig. 4-5B 
shows results for the 75 high-grade lesions, and again the median percentages of positive 
tumour samples for one, two and three attempts are all significantly different (p < 0.05, 
Wilcoxon signed rank test), with the exception of the median sampling percentages for 
two and three biopsy attempts when RMSE = 1 mm.  Furthermore, no significant 
differences were observed between the proportions of positive samples for one, two and 
three biopsy attempts on all-grade and high-grade lesions at corresponding RMSE levels 
(p > 0.05; Wilcoxon rank sum test). 
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Figure 4-5: The median ± interquartile range rate of cancer positive samples per 1000 
biopsy simulations, for (A) 307 lesions of all Gleason grades and (B) 75 high-grade 
lesions, as a function of RMSE for one, two and three biopsy attempts. 
 
 
4.5 Discussion 
4.5.1 Experiment 1 – Relationship of needle delivery error and 
percent core involvement 
We observed that different needle delivery errors have different levels of impact 
on the variability in observed core involvement (Fig. 4-3A), with the greatest changes 
occurring between a RMSE of 1 mm and 4 mm. At an RMSE = 4 mm (as has been 
observed in practice11), we observed a median 95–5 percentile core involvement range of 
6.2 mm for each biopsy attempt, with a maximum value of 17.0 mm. Considering a 
typical total core length of 18 mm, this median range of variability constitutes more than 
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1/3 of a full 18 mm long prostate biopsy core. This observation is important in the 
context of the use of percent core involvement as a means for determining 
appropriateness of active surveillance13,14; the same patient could have very different 
percent core involvement values from biopsies taken in immediate succession, even with 
biopsies aimed at the same tumour targets. These differences could be large enough to 
influence the decision of active surveillance vs. definitive treatment14. For high-grade 
tumours (Fig. 4-3B), we observed a similar pattern with a median 5–95 percentile core 
involvement range of 7.3 mm at RMSE = 4 mm, with a maximum value of 17.0 mm. 
Based on our observation of a positive correlation between the 95–5 percentile 
core involvement range and tumour diameter reported in Section 4.4.1, this implies 
greater variability in core involvement arising from needle delivery error for larger 
tumours. Although this may seem counterintuitive (as larger tumours should be easier to 
hit), because an on-target biopsy of a large tumour yields a longer core length than for a 
small tumour, there is a greater potential range of core involvement lengths for large 
tumours. 
Comparing Fig. 4-3A to Fig. 4-3B, we did observe significant differences 
between all- and high-grade tumours for this measurement when RMSE ≥ 4 mm.  For 
lesions of all grades, we observed median 95–5 percentile core involvement values of 6.2, 
7.1 and 7.3 mm, and maximum values of 17.0, 18.0 and 18.0 mm, for RMSE values of 4, 
5 and 6 mm respectively.  Likewise for high-grade lesions, we observed median 95–5 
percentile core involvement values of 7.3, 8.1 and 8.6 mm, and maximum values of 17.0, 
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18.0 and 18.0 mm, for RMSE values of 4, 5 and 6 mm respectively.  These results imply 
that when RMSE ≥ 4 mm, targeting of high-grade lesions may lead to an increase in core 
involvement variability observed after repeated biopsy attempts when compared to 
lesions of all grades.  However, this difference is rather small, with an average difference 
in 95–5 percentile core involvement of ~1 mm observed between the two lesion groups.  
It must also be noted that in the event that a sample of high-grade cancer is obtained 
through biopsy, the core involvement measure may be rendered moot.  For example, a 
biopsy core which contains PCa with a Gleason Score of 7 but a core involvement < 50% 
would still be deemed to be clinically significant by the NCCN Clinical Practice 
Guidelines for Prostate Cancer14.  No significant differences were observed when RMSE 
≤ 3 mm. 
 
4.5.2 Experiment 2 – Relationship between needle delivery error 
and proportion of biopsy attempts that miss the target  
We observed that increasing needle delivery error leads to an increase in the 
proportion of biopsy attempts that will entirely miss the tumour, for both all-grade and 
high-grade tumours. The median proportion of misses monotonically increased as RMSE 
increased. At RMSE = 4 mm, a median of 9% of the simulated biopsy attempts missed all 
cancer and contained only non-cancerous tissue samples (Fig. 4-4A). However, the 
spread of this proportion is large and a maximum percentage of 61% of biopsy attempts 
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missed all tumour tissue at this level of RMSE.  The same trend was observed for the 
group of high-grade lesions as well, with a median percentage of 9% and maximum of 
58% of biopsy attempts missing all cancer tissue.  This corroborates our results 
demonstrating the need for more than one biopsy attempt to successfully sample smaller 
tumours, as discussed in Section 4.5.3. 
We also observed a significant negative correlation between tumour diameter and 
proportion of biopsy attempts where the tumour is entirely missed.  This implies that the 
larger a tumour’s diameter, the more likely some portion of it will be sampled by the 
biopsy needle, which is an expected result.   
We did not observe significant differences between all- and high-grade tumours 
for this measurement.  However, our inability to detect significant differences between 
proportions of tumour misses for all-grade and high-grade tumours was not surprising, as 
no significant difference was observed in tumour surface area or diameter between 
lesions of the all grade and high grade groups (p > 0.05; Wilcoxon rank sum test). 
 
4.5.3 Experiment 3 – Relationship between number of biopsy 
attempts and probability of a tumour sample   
Fig. 4-5A shows that for RMSE ≥ 3 mm, a significantly higher median tumour 
sampling probability is achieved when two biopsy attempts are made as opposed to one.  
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Probability increases of 3%, 8%, 13% and 17% were observed between one and two 
biopsy attempts for RMSE values of 3, 4, 5 and 6 mm respectively.  Furthermore, 
probability increases of 3%, 9%, 15% and 21% can be obtained over this same RMSE 
range when making three biopsy attempts relative to one.  In comparing Fig. 4-5A and 4-
5B, no significant differences were observed between all-grade and high-grade lesions 
with respect to this measurement, for one, two or three biopsy attempts. 
The results shown in Fig. 4-5 are concordant (within 5%) with estimated sampling 
probabilities in our previously published work that used MRI-defined biopsy targets in 
3D11 for RMSE ≤ 3 mm. For RMSE ≥ 4, mm, the sampling probabilities in this work are 
higher than our previous experiments (<25% greater). This discrepancy could be 
explained by simulation of biopsy using 2D lesions in this work as opposed to 3D, and 
also the presence of microscopic cancerous regions on histology that are generally 
invisible on MRI; these will be captured within the biopsy cores in simulations conducted 
in this paper but not in those conducted in our previous work. 
 
4.5.4 Clinical Relevance   
To the best of our knowledge, this is the first study to demonstrate a significant 
effect of prostate biopsy needle guidance error on the percent core involvement of high-
grade cancer and cancer of all grades, using gold standard histology imaging.  
Furthermore, this is the first study to compare the core involvements obtained when 
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specifically targeting high grade cancer versus cancers of all grades.  This was made 
possible by the unprecedented level of detail of the histology tumour contouring and 
spatial localization of different intra-tumoural Gleason grades. Our data showed that for 
expected needle guidance errors, repeated biopsies of the same target can yield percent 
core involvement measures with sufficient variability to influence the decision for active 
surveillance vs. definitive treatment. Our data also shows that this issue may be mitigated 
by making more than one biopsy attempt at selected tumour targets.  
4.5.5 Limitations   
Although the use of histology imaging for simulated biopsy affords the ability to 
characterize percent core involvement and distribution of cancer grades in the core using 
a recognized gold standard, due to clinical limitations histology images are 2D, sliced 
approximately in the axial orientation, and acquired sparsely throughout the midgland 
(every 3–5 mm). Thus, the conclusions of this study are made under the assumption that 
apparent prostate tumour size and shape are invariant to tissue slicing orientation. This 
study is therefore complementary to previous work addressing these research questions 
using lesion contours on MRI, which are 3D but subject to inaccuracy and observer 
variability11,12,17.  
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4.6 Conclusions 
Image-guided prostate biopsy can target needles to suspicious areas within the 
prostate with the aim of obtaining an earlier definitive diagnosis and treatment plan. Our 
data, based on gold standard radical prostatectomy histology, demonstrated that needle 
delivery error can have a substantial impact on the probability of obtaining a sample and 
on the percent core involvement when a sample is obtained, for both high-grade cancer 
and cancers of all grades. We also observed that when RMSE ≥ 4 mm, targeting of high-
grade lesions may result in higher core involvement variability observed after repeated 
biopsy attempts when compared to lesions of all grades.  These parameters are important 
to patient risk stratification and the decision to pursue active surveillance vs. definitive 
treatment. This issue can be mitigated by making multiple biopsy attempts at selected 
targets, increasing the probability of obtaining a sample that correctly characterizes the 
extent and grade of the patient’s cancer. 
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Chapter 5 
 
5 Conclusions and future work suggestions 
 
5.1 Overview of rationale for research project: 
Prior to this work, there has been substantial research showing the advantages of 
MRI-targeted 3D TRUS-guided fusion biopsy over 2D TRUS-guided systematic biopsy.  
These fusion biopsy systems were developed with the purpose of improving upon the 
spatial information provided by 2D TRUS, and also to allow for targeting of lesions 
defined on MRI during biopsy, using image registration1-5.  To date, there have been 
numerous studies which have shown an increase in cancer-positive core rates for fusion 
biopsy, relative to systematic TRUS-guided biopsy6-10.  A systematic review was also 
conducted comparing 3D TRUS-guided fusion biopsy with 2D TRUS-guided systematic 
biopsy, and it was found that fusion biopsy detected more clinically significant cancers 
using fewer cores compared with systematic biopsy (median 33% cancer-positive core 
rate, range 13-50% for fusion biopsy; median 24% cancer-positive core rate, range 5%-
52% for systematic biopsy)11.  Furthermore, a recent multicentre and randomized trial at 
25 centres in 11 countries found the use of MRI prior to biopsy led to fewer men 
undergoing biopsy, and the use of MRI-targeted fusion biopsy led to less overdetection of 
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clinically insignificant cancer, with fewer biopsy cores obtained compared with standard 
2D TRUS-guided systematic biopsy12.  This study also showed a significant increase in 
the detection of clinically significant cancer when fusion biopsy was used, compared with 
the standard systematic biopsy group12. 
While it is not a focus of this thesis, another approach to TRUS-guided biopsy of 
prostate MRI-defined lesions is “cognitive registration.” This approach involves intuitive 
visual alignment between MRI lesions and TRUS guidance13.  While it has been shown 
that the use of MRI for cognitive fusion led to an increased detection rate of clinically 
significant cancer and less overdetection of clinically insignificant cancer compared with 
systematic biopsy12, consensus has not yet been reached comparing the efficacy of the 
cognitive vs. software fusion approaches. Two studies have reported that biopsy targeting 
of clinically significant MRI lesions using cognitive registration resulted in inferior 
cancer detection rates compared with MRI-TRUS fusion14,15, while another study found 
no significant difference in cancer detection rates between the two approaches8. Further 
investigation is warranted, as the greatest benefit for MRI-TRUS fusion over cognitive 
registration may be achieved for tumours that are small but still clinical significant. 
Despite substantial research being conducted in order to investigate the potential 
improvements in patient care achieved through the use of fusion prostate biopsy, prior to 
this thesis, there remained a lack of knowledge in terms of target optimization for 
placement fusion biopsy needles.  At the time of the writing of this thesis, the author is 
aware of one other study which investigated how fusion biopsy needle delivery error 
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affects cancer detection, by van de Ven et al.16 This led to the observation that the 
positive core rate is related to the biopsy system error in delivering the needle to the 
intended tumour target.  Furthermore, a recent study by Lu et al.17 showed that for the 
Artemis fusion biopsy system, cancer detection rates improve as the number of biopsy 
cores increases from one to five, but no significant increase in detection rate was 
observed beyond five cores.  For cancers of any Gleason grade, positive core rates of 
69% and 84% were reported for one biopsy attempt and two biopsy attempts respectively.  
These results show close agreement with our results presented in Figure 2-3 and Figure 2-
5 for a needle delivery error of 5 mm.  While we estimated the needle delivery error of 
the Artemis system to be 3.5 mm in Chapter 2, it should be noted that our error model did 
not account for needle deflection during biopsy, and in reality this error may be larger 
than 3.5 mm in practice. 
What is envisioned for this field after the completion of the work presented in this 
thesis, is that needle delivery error estimates for any MRI targeted, 3D TRUS-guided 
fusion prostate biopsy system could be used in conjunction with the results presented in 
this thesis in order to aid any physician performing a targeted biopsy in deciding the 
number and spatial locations of targeted biopsy needles in order to achieve a desired 
probability of sampling the lesion being targeted.  Specifically, it is envisioned that the 
lessons presented in this work could be incorporated into an onboard software module 
that provides automatic selection of biopsy target locations given the error characteristics 
of any particular biopsy system (see Section 5.2.2). 
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5.2 Project summary and conclusions 
The work presented in this thesis represents several steps toward the overarching 
goal of more accurate characterization of cancer burden for PCa patients, as well as 
earlier diagnosis of PCa while it remains confined to the gland and curable.  These steps 
toward this goal were achieved through the development of a fusion biopsy simulation 
software platform which allowed for the investigation of how needle delivery error of 
MRI-targeted, 3D TRUS-guided “fusion” prostate biopsy affects the probability of 
successfully sampling prostatic tumours and the estimation of cancer burden for 
suspected PCa patients.  This work was divided into three chapters, which are 
summarized below. 
In Chapter 2, the probability of obtaining a positive tumour sample in a single 
biopsy core was estimated for 81 3D suspicious regions contoured on MRI by two 
radiologists. The results indicated that more than one core must be taken from the 
majority of tumours to achieve a sampling probability of 95% or greater for a biopsy 
system with an overall error ≥ 3.5 mm.  Furthermore, it was shown that despite the 
potential impact of differences in tumour shape on positive sampling probability, tumours 
with high (> 95%) probability of positive sampling can be distinguished from those with 
lower sampling probability based on tumour volume.  The upper bound of the 99% 
prediction interval for the lesion volumes with sampling probability < 95% was 1.05 
cm3, which provides some insight into the largest tumours that cannot be successfully 
sampled in one biopsy core with 95% confidence.  It was also observed through 
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comparison with a previously published method that the assumption of spherical tumour 
shape can lead to an overestimation of positive sampling probabilities. Although this 
observation was significant (p < 0.05), the overestimation varied with biopsy system 
RMSE and the practical importance of this observation depends on both tumour 
asphericity and biopsy system needle delivery error.  The results from Chapter 2, 
especially the finding that multiple biopsy attempts are necessary in order to achieve a 
sampling probability ≥95% for the majority of prostate lesions defined on MRI, were 
critical to the justification of development of the biopsy simulation software platform 
which allowed the simulation of multiple biopsy attempts and different targeting schemes 
for each lesion, as discussed in Chapter 3. 
In Chapter 3, a “ring” targeting strategy was proposed, with the intention of 
compensating for a systematic error of known magnitude, but unknown direction.  The 
results suggest that the optimal targeting scheme for prostate biopsy depends on the 
relative levels of systematic and random errors in the system. Where systematic error 
dominates, a ring targeting scheme may yield improved probability of tumour sampling, 
particularly for small tumours.  Furthermore, the work in Chapter 2 was focused 
primarily on the probability of obtaining any amount of PCa within the biopsy core, 
without considering the core involvement (i.e. the proportion of the biopsy core that 
contains tumour tissue), which is an important measure used to determine the clinical 
significance of a patient’s PCa188,19.  In Chapter 3, I compared the probabilities of 
obtaining a core involvement ≥ 50% (from 55 out of the 81 total lesions which were 
large enough to obtain this core involvement) when using either a ring or centroid 
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targeting strategy.  Similar to the first study in Chapter 3, I found that when systematic 
error dominates, a ring targeting scheme may yield improved probability of tumour 
sampling.  However, the probabilities of obtaining a 50% core involvement were 
substantially lower compared with the probabilities of obtaining any amount of PCa 
within the core, for both targeting strategies.  While this Chapter represents a step toward 
improving the manner in which lesions are targeted using fusion biopsy, a prospective 
trial will ultimately be needed to determine the improvement in positive yield achieved 
through optimization of needle target selection. The data presented in this paper could be 
incorporated into an onboard software module that provides the operator with biopsy 
target locations given the error characteristics of any particular biopsy system (see 
Section 5.2.2). 
An important limitation of the work presented in Chapters 2 and 3 is that MRI-
defined regions of suspicion were used as biopsy simulation targets, without histologic 
confirmation of the core involvements and high-grade cancer yield resulting from biopsy 
simulation. In Chapter 4, I addressed this by using histologically confirmed PCa tumours 
as contoured on digital histology images by genitourinary pathologists to conduct biopsy 
simulations and report core involvement and high-grade cancer yield as a function of 
biopsy system error. By using histology image contours to define tumour targeting, this 
work modeled idealized tumour targeting, wherein boundary delineation on the planning 
image was exactly concordant with lesions on histopathology. Results from our 
simulations thus represented a best-case scenario, since lesions contoured by experts on 
MRI are not volumetrically concordant with true histologic lesionsError! Reference source not 
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found.,21.  As histology slices are inherently 2D and oriented approximately axially, our 
simulations were conducted in 2D under the assumption that prostate tumour size and 
shape are invariant to slicing angle. This was a necessary compromise to reap the benefits 
of the enhanced core involvement and grade information provided by histology imaging, 
compared to MRI.  Our data, based on gold standard radical prostatectomy histology, 
demonstrated that needle delivery error can have a substantial impact on the probability 
of obtaining a sample and on the percent core involvement when a sample is obtained, for 
both high-grade cancer and cancers of all grades. We also observed that when RMSE ≥ 4 
mm, targeting of high-grade lesions may result in higher core involvement variability 
observed after repeated biopsy attempts when compared to lesions of all grades.  It must 
be noted that in the event that a sample of high-grade cancer is obtained through biopsy, 
the importance of core involvement in estimation of tumour burden may be diminished18.  
However, these parameters are important to patient risk stratification and the decision to 
pursue active surveillance vs. definitive treatment. In concordance with the findings 
presented in Chapters 2 and 3, I observed that this issue can be mitigated by making 
multiple biopsy attempts at selected targets, increasing the probability of obtaining a 
sample that correctly characterizes the extent and grade of the patient’s cancer. 
In this thesis, we have demonstrated the effects of fusion biopsy needle delivery 
error on prostatic lesion biopsy sampling probabilities.  According to our hypotheses in 
Section 1.5.1, more than one biopsy attempt should be necessary to achieve probabilities 
≥ 95% of both obtaining a PCa-positive sample, and obtaining a core involvement ≥ 
50% for lesions large enough to obtain a core involvement of that size.  It was shown in 
144 
 
 
 
Chapter 2 that for a fusion biopsy system random needle delivery error of 3.5 mm, the 
sampling probability < 95% for 60 out of 81 lesions (74% of lesions) in the dataset when 
one biopsy attempt is made.  While the study conducted in Chapter 2 was performed 
using suspicious prostatic lesions contoured on MRI and not pathologist-confirmed PCa 
from histology, the experiments conducted in Chapter 4 used tumours from gold standard 
prostate histology to simulate biopsy attempts, and it was shown that the sampling 
probability < 95% for 180 out of 307 tumours (59% of tumours) when making one 
biopsy attempt for a fusion biopsy system with a random needle delivery error of 4 mm.  
When making two biopsy attempts, sampling probability < 95% for only 80 out of 307 
tumours (26% of tumours), therefore showing that sampling probability ≥ 95% for the 
majority of PCa tumours when two or more biopsy attempts are made. 
In the results presented in Chapter 3, it was observed that for a fusion biopsy 
system with a random needle delivery error ≥ 4 mm and systematic error ≤ 6 mm, the 
probability of obtaining a 50% core involvement is < 95% for the majority of tumours of 
volume < 1 cm3 when ≤ 4 biopsy attempts are made, and also for the majority of tumours 
of volume ≥ 1 cm3 when ≤ 2 biopsy attempts are made.  It was observed that when three 
biopsy attempts are made for tumours of volume ≥ 1 cm3, the probability of obtaining a 
50% core involvement is ≥ 95% for a fusion biopsy system with a random needle 
delivery error ≤ 4 mm and a systematic error ≤ 2 mm.  Likewise, the probability of 
obtaining a 50% core involvement is ≥ 95% when four biopsy attempts are made on 
tumours of volume ≥ 1 cm3, for a fusion biopsy system with a random needle delivery 
error ≤ 4 mm and a systematic error ≤ 3 mm.  These results were observed for both the 
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centroid and ring targeting strategies presented in Chapter 3.  Therefore, it was observed 
that multiple biopsy attempts are necessary to achieve a probability ≥ 95% of obtaining a 
50% core involvement for the majority of tumours in our dataset, including those of 
volume ≥ 1 cm3. 
Thus, the central hypotheses of this thesis were confirmed through the findings 
presented in Chapters 2, 3 and 4. 
 
5.3 Advancements in knowledge achieved through completion of 
this work 
Through the completion of this thesis, we have advanced knowledge in this field 
by providing: (1) insight into the maximum tumour volume that cannot be successfully 
sampled in one biopsy core with 95% confidence; (2) evidence that an assumption of 
spherical tumour shape results in a consistent overestimation of tumour sampling 
probability; (3) evidence that ring targeting may yield improved probability of tumour 
sampling for fusion biopsy systems where systematic error dominates over random error; 
(4) evidence that needle delivery error introduces enough variability in core involvement 
measures for repeated biopsies of the same tumour target to influence the decision of 
active surveillance vs. definitive treatment, for both high grade PCa and for PCa of all 
grades; and (5) evidence that targeting of high grade lesions may result in higher core 
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involvement variability after repeated biopsy attempts when compared with lesions of all 
grades. 
 
5.4 Suggestions for future work: 
5.4.1 Simulations using prostate histopathology co-registered with 
MRI 
The work presented in this thesis represents, to the best of my knowledge, the first 
study of its kind to investigate the effects of prostate fusion biopsy needle delivery error 
on tumour sampling probabilities and cancer burden estimation.  However, in the studies 
presented in this thesis, either radiologist-defined contours on MRI (Chapters 2 and 3) or 
gold standard radical prostatectomy histology (Chapter 4) were used to determine biopsy 
needle target locations and evaluate the contents of the simulated biopsy cores.  
Furthermore, the experiments described within this thesis were conducted under the 
assumption that needle delivery error is invariant to tumour location within the prostate. 
While the work detailed in this thesis represents necessary early steps in the investigation 
of this problem, the next logical step is to use my fusion biopsy simulation software 
platform to simulate situations which are more closely related to how targeted fusion 
biopsies are planned and evaluated in a clinical setting.   
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We have the ability in our research laboratory to accurately fuse whole-mount 
prostatectomy histology with in-vivo MRI obtained prior to surgery22,23 (Fig. 5-1).  This 
fusion has been performed for 52 prostatectomy specimens as part of a clinical trial at our 
centre, where MRI contours have been performed by four radiologists for 18 of those 
cases to date.  This involves the same histology dataset as was used in Chapter 4 of this 
thesis, and PCa has been contoured on all histology images by a physician trained in PCa 
morphology, with contouring confirmed by a genitourinary pathologist.  Using this 
dataset of co-registered prostate histology and in vivo MR images, my biopsy simulation 
platform can be used to determine biopsy target locations using the radiologist-contoured 
MR image dataset, but then evaluate biopsy core involvement and aggressiveness of PCa 
in each biopsy core based on the co-registered histology data.   
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Figure 5-1: Showing co-registration between (A) whole-mount prostatectomy histology 
and (B) in-vivo T2W MRI.  The location of PCa on histology is delineated in blue, while 
suspicious lesion delineation performed by a radiologist on MRI is shown in red.  While 
the radiologist was correct in assessing the location of PCa in this case, the lesion 
margins on MRI do not match with the tumour margins as delineated on histology. 
A
B
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This approach can be used to investigate the following research questions, enumerated 1 
through 5 below. 
1)  When using radiologist-defined contours to select biopsy needle target locations in the 
presence of biopsy system needle delivery error, what is probability of obtaining a 
positive sample of PCa of any grade within the biopsy core as evaluated using gold-
standard co-registered histology? 
2)  What is the probability of obtaining a positive sample of high grade PCa (Gleason 
Score ≥ 4+3) within the biopsy core? 
3)  When using radiologist-defined contours to select biopsy needle target locations, what 
is the impact of biopsy needle delivery error on the core involvement of PCa obtained 
within a biopsy core? 
4)  How do the results from this new prostate biopsy model compare to those presented in 
this thesis? 
5) How can the biopsy tumour targeting strategies proposed in this thesis be adapted to 
adjust for the misalignment between MRI lesions and PCa tumours? 
The findings of this particular study could be used to improve fusion biopsy 
targeting through the following avenues: (1) determining the maximum tumour volume 
that cannot be sampled with 95% confidence in a given number of biopsy attempts when 
performing MRI-targeted 3D TRUS-guided biopsy, evaluated using prostate histology as 
opposed to evaluated using only MRI-contours as in Chapter 2 of this thesis; (2) 
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determining the maximum high grade tumour volume that cannot be sampled with 95% 
confidence in a given number of biopsy attempts; (3) determining the number of biopsy 
attempts necessary to achieve a 50% core involvement for tumours which are large 
enough for such a core involvement to be obtained, given lesion volume; and (4) 
determining potential improvements to the centroid and ring targeting strategies for 
biopsy needle target selection proposed in this thesis, in order to adjust for misalignment 
between MRI-lesions and PCa tumours. 
 
5.4.2 Implementation of adapted fusion biopsy targeting strategies 
in clinic 
The findings presented in this work could be directly beneficial in ongoing 
clinical studies in prostate cancer.  Specifically, lessons learned on the topic of prostate 
biopsy target selection could be translated into clinic through incorporation into the 
graphical user interface of any fusion biopsy system currently being used to perform 
targeted prostate biopsies.  I envision that the biopsy system display could be updated to 
indicate the number and spatial locations of biopsy targets necessary to achieve any 
desired probability of successfully sampling the suspicious lesions contoured on MRI, 
given the estimated needle delivery error for the particular biopsy system and the size and 
shape of the lesions to be targeted (Fig. 5-2A).   
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Alternatively, a less stringent targeting approach could be taken, wherein a colour 
map is overlaid onto the MR contours indicating the probability of successfully sampling 
the region of interest (Fig. 5-2B).  This would allow the operating clinician to have more 
freedom in selecting where biopsy needles are placed, given indicated probabilities of a 
successful sample.  Furthermore, these colour maps could continue to update as biopsy 
cores are taken (i.e. indicating an increase in sampling probability as more biopsy 
attempts are made).  The implementation of such a targeting system has the potential to 
increase the tumour sampling probability for fusion biopsy systems which are already 
used in clinical practice. 
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Figure 5-2: A probe’s eye view (i.e. looking down the axial direction of a TRUS probe) 
of 3 suspicious lesions contoured on MRI and registered to 3D TRUS. (A) Indicating 
biopsy target locations using both the centroid and ring targeting strategies (see Chapter 
3) in order to achieve the operator’s desired probability of obtaining a successful sample 
from these regions. (B) Colour maps overlaid onto the MRI contours indicating the 
probability of a successful sample given biopsy target location. 
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